Trigeminal neuralgia …

Jennifer Robblee MD MSc FRCPC

Headache & Pain

Updated 01.27.2026
Released 05.08.2001
Expires For CME 01.27.2029

Trigeminal neuralgia

Author: Jennifer Robblee MD MSc FRCPC

See Contributor Disclosures

Editor: Hsiangkuo Yuan MD PhD FAHS

Cite this article

Trigeminal neuralgia

In This Article

Quick Link

Introduction

Overview

This article delves into the complexities of trigeminal neuralgia, a disorder characterized by severe neuralgiform pain within the trigeminal distribution. The intensity of this pain is so profound that it has earned the condition a grim moniker, “the suicide disease.” The author provides an in-depth exploration of its epidemiology, diagnosis, and evidence-based treatments. The diagnostic section outlines the categorization per The International Classification of Headache Disorders, third edition (ICHD-3), shedding light on both primary and secondary etiologies. The section on treatment discusses pharmacological agents, including vixotrigine and basimglurant, which are under clinical trials, along with an overview of contemporary surgical approaches.

Key points

	• Trigeminal neuralgia presents as recurrent paroxysms of unilateral, brief electric shock-like pains, abrupt in onset and termination, limited to the distribution of the trigeminal nerve.
	• Trigeminal neuralgia can be categorized as classical, idiopathic, or secondary. Painful trigeminal neuropathy instead presents with burning pain, numbness, or tingling with causes including zoster, postherpetic neuralgia, and trauma.
	• Classical trigeminal neuralgia is attributed to demyelination of the dorsal root entry zone from vascular compression, leading to spontaneous or triggered discharges of the nerve, whereas idiopathic trigeminal neuralgia may be due to molecular changes, channelopathies, or electrophysiological abnormalities.
	• Brain MRI is recommended in all patients without contraindications.
	• First-line pharmacotherapy includes carbamazepine and oxcarbazepine; second-line pharmacotherapy includes lamotrigine, gabapentin, pregabalin, baclofen, phenytoin, and botulinum toxin type A.
	• Microvascular decompression is the gold standard surgical treatment for classical trigeminal neuralgia.

Historical note and terminology

Descriptions of trigeminal neuralgia date back to antiquity, with early references by Galen and Aretaeus of Cappadocia in the second century AD and later by Avicenna in the 11th century (07; 151). The term “tic douloureux” was introduced by Nicolas André in 1756 to describe paroxysmal facial pain he attributed to nerve compression (34). John Fothergill provided the first comprehensive clinical account in 1773, describing abrupt, unilateral, electric shock–like facial pain triggered by light touch or chewing (48; 53; 151; 143).

During the 19th and early 20th centuries, accumulating observations by Bell, Trousseau, and others distinguished trigeminal neuralgia from other facial pain syndromes and led to the concept of “epileptiform neuralgia,” emphasizing its paroxysmal nature (176; 73; 43). Oppenheim later noted its association with multiple sclerosis (132).

Pharmacological therapy advanced in the mid-20th century when Bergouignan first used phenytoin in 1942 and Blom introduced carbamazepine in 1963, establishing anticonvulsants as the cornerstone of treatment (24; 30; 73). Modern surgical treatment originated with Dandy’s 1925 observation of vascular loops compressing the trigeminal root (47; 43). The microvascular decompression technique was refined by Gardner and Miklos and popularized by Jannetta in the 1970s, whereas radiofrequency ablation was introduced by Sweet and Wepsic in 1974 (75; 170; 92).

Clinical manifestations

Presentation and course

	• Recurrent, unilateral, brief, electric shock–like facial pains in a trigeminal distribution are often triggered by innocuous stimuli.
	• V2 is most commonly involved, followed by V3, then V1.
	• Many patients first seek dental care.
	• Some patients report concomitant continuous or near-continuous background pain between paroxysms.
	• Painful trigeminal neuropathies differ from typical trigeminal neuralgia by continuous burning pain or with sensory deficits, often resulting from herpes zoster, trauma, systemic disease, or iatrogenic causes (eg, neuroablative procedures).

Overview of clinical presentation

The ICHD-3 diagnostic criteria describe trigeminal neuralgia as recurrent, unilateral, brief, electric shock-like pains with abrupt onset and termination limited to the distribution of the trigeminal nerve (85). The maxillary (V2) division is most commonly affected, followed by the mandibular (V3) and ophthalmic (V1) divisions (159). Because V2 and V3 are often involved, patients frequently first seek dental evaluation for onset presenting as odontalgia (05). The sharp or electrical paroxysms last seconds to minutes and can occur in rapid succession, followed by a brief refractory period. In approximately 50% of cases, continuous or near-continuous pain persists between attacks (112; 85). Pain is commonly triggered by innocuous stimuli, such as washing, shaving, or light touch, or simple facial movements, such as eating, drinking, smiling, or talking. Occasionally, non-tactile sensory stimuli like bright lights or loud sounds can trigger attacks. Over time, the attacks may become more frequent, severe, and disabling, causing marked psychosocial and functional impairment. Although not commonly discussed, older literature described pre-trigeminal neuralgia as presentation of toothache or sinusitis-like pain lasting hours days to years before actual presentation (72).

ICHD-3 Diagnostic criteria for trigeminal neuralgia

Under Part III: Neuropathies & Facial Pains and other headaches, the ICHD-3 lists Painful lesions of the cranial nerves and other facial pain (85). Here trigeminal neuralgia is listed under 13.1.1 and broken into several subcategories. Subtypes are classical, secondary, and idiopathic. Painful trigeminal neuropathy is distinct and features continuous burning pain and sensory change from neural injury. The first-digit level diagnostic criteria for trigeminal neuralgia are as follows:

A. Pain has all of the following characteristics:
	1. Lasting from a fraction of a second to 2 minutes
	2. Severe intensity
	3. Electric shock-like, shooting, stabbing, or sharp in quality
B. Precipitated by innocuous stimuli within the affected trigeminal distribution
C. Not better accounted for by another ICHD-3 diagnosis

Classical trigeminal neuralgia

This subtype meets ICHD-3 criteria for trigeminal neuralgia when associated with neurovascular compression and morphological nerve changes demonstrated on MRI, without other secondary causes (85). Its diagnostic criteria are as follows:

	(A) Recurrent paroxysms of unilateral facial pain fulfilling criteria for 13.1.1 trigeminal neuralgia.
	(B) Demonstration on MRI or during surgery of neurovascular compression (not simply contact), with morphological changes in the trigeminal nerve root.

Compression typically occurs at the root entry or transition zone of the trigeminal nerve, most often from the superior cerebellar artery (102). Other vascular compressions may include veins or vertebrobasilar dolichoectasia (103; 147). Morphological nerve changes can include atrophy, demyelination, or microvascular alterations. Contact between the trigeminal nerve and a vessel is insufficient to cause pain and is common in asymptomatic individuals (104). Classical trigeminal neuralgia is subdivided into purely paroxysmal forms or those with concomitant continuous background pain.

Secondary trigeminal neuralgia

This subtype meets criteria for trigeminal neuralgia but is associated with an identifiable secondary cause other than neurovascular compression (85). Its diagnostic criteria are as follows:

	(A) Recurrent paroxysms of unilateral facial pain fulfilling criteria for 13.1.1 trigeminal neuralgia, either purely paroxysmal or associated with concomitant continuous or near-continuous pain.
	(B) An underlying disease has been demonstrated that is known to be able to cause, and explain, the neuralgia.
	(C) Not better accounted for by another ICHD-3 diagnosis.

Common causes include multiple sclerosis, mass lesions, and structural abnormalities. Trigeminal neuralgia due to multiple sclerosis results from demyelinating plaques within the pons or trigeminal root entry zone and can be bilateral. Lesions such as schwannomas, meningiomas, epidermoid cysts, acoustic neuromas, and cholesteatomas can produce similar symptoms (44). Other causes include skull base deformities, connective tissue disease, arteriovenous malformations or fistulas, and genetic syndromes.

Idiopathic trigeminal neuralgia

This subtype meets ICHD-3 criteria but has no identifiable source of nerve injury or compression on MRI or electrophysiological studies (85). Its diagnostic criteria are as follows:

	(A) Recurrent paroxysms of unilateral facial pain fulfilling criteria for 13.1.1 trigeminal neuralgia, either purely paroxysmal or associated with concomitant continuous or near-continuous pain.
	(B) Neither 13.1.1.1 classical trigeminal neuralgia nor 13.1.1.2 secondary trigeminal neuralgia has been confirmed by adequate investigation including electrophysiological tests and MRI.
	(C) Not better accounted for another ICHD-3 diagnosis.

Contact between a vessel and the trigeminal nerve without morphological nerve changes (atrophy, displacement, or distortion) also fits this category. Idiopathic trigeminal neuralgia without neurovascular conflict may be more likely to be medically refractory (03). It is also divided into purely paroxysmal and concomitant continuous-pain subtypes.

Painful trigeminal neuropathy

This group differs from trigeminal neuralgia in that nerve damage is present. Pain is often continuous as opposed to paroxysmal. It is often described as burning, squeezing, or “pins and needles” (85). Sensory changes can include both positive (hyperalgesia, allodynia) and negative (hypoesthesia, hypoalgesia) findings. Superimposed paroxysms may occur but are not predominant. Mechanical allodynia and cold hyperalgesia are common, and affected areas are larger than the punctate trigger zones of trigeminal neuralgia. Subtypes include those due to herpes zoster, postherpetic neuralgia, post-traumatic injury, other disorders, and idiopathic forms. Each is defined by specific ICHD-3 criteria.

The Barrow Neurological Institute Pain Scale and the Visual Analog Scale are frequently used to rate trigeminal neuralgia pain and outcomes (38; 193).

Painful trigeminal neuropathy attributed to herpes zoster

Acute zoster–related trigeminal neuropathy presents with unilateral burning, stabbing, or aching pain within the affected branch, most often the ophthalmic (V1) division. Pain coincides with vesicular rash or appears within a few days. Allodynia may accompany cutaneous inflammation, and corneal involvement is frequent. When symptoms persist for more than 3 months, the condition is classified as trigeminal post-herpetic neuralgia (85).

Post-herpetic trigeminal neuropathy

This chronic form, referred to as trigeminal post-herpetic neuralgia in the ICHD-3, follows a herpes zoster infection of the trigeminal nerve and is defined by pain persisting or recurring for at least 3 months after rash onset (85). It is characterized by constant burning pain, often with severe tactile allodynia, and frequently affects the ophthalmic division, leading to ocular surface irritation or keratitis. Although some sources call it a neuralgia, it is categorized in the ICHD-3 within the heading of painful trigeminal neuropathy due to its typical features, like burning pain and allodynia.

Painful post-traumatic trigeminal neuropathy

This form occurs after mechanical, surgical, dental, or radiation-related trauma to the trigeminal nerve. Pain typically develops within 6 months of injury and is described as burning, squeezing, or stabbing with superimposed paresthesia. Sensory loss and allodynia are common. Radiation-related cases may have a delayed onset. This form may also develop as an iatrogenic complication following neuroablative procedures for trigeminal neuralgia (85).

Painful trigeminal neuropathy attributed to another disorder

This form represents continuous or recurrent pain due to systemic, infectious, inflammatory, or neoplastic disease known to injure the trigeminal nerve. It was previously referred to as anesthesia dolorosa. Causes include multiple sclerosis, sarcoidosis, connective-tissue disorders, vasculitis, and malignancy. Pain is often bilateral or asymmetric and may include both paroxysmal and continuous components (85; 136).

Idiopathic painful trigeminal neuropathy

This form meets criteria for trigeminal neuropathy with sensory loss and continuous pain, but no underlying cause is identified despite adequate investigation. Symptoms are typically mild to moderate, with a stable course. Long-term follow-up is recommended to rule out evolving secondary causes (85).

Visual analog scale

(From: Yeung AW, Wong NS. The historical roots of visual analog scale in psychology as revealed by reference publication year spectroscopy. Front Hum Neurosci. 2019;13: 86.)

Prognosis

The first step in management is pharmacotherapy. Older teachings noted that trigeminal neuralgia worsens over time, but a study of 200 patients on carbamazepine or oxcarbazepine demonstrated that only 2% to 3% developed worsening over time (55). In fact, remissions lasting weeks to years have been reported in almost two thirds of patients (112). Patients with concomitant continuous pain are thought to have a poorer prognosis (44).

Surgery is generally reserved for medically refractory cases. Imaging predictors have been investigated, but none have been established as biomarkers. A 2025 MRI study found that ipsilateral reductions in fractional anisotropy on diffusion tensor imaging predicted long-term postoperative pain relief following microvascular decompression or rhizotomy (49). However, another diffusion tensor imaging study found no difference between responders and nonresponders (178). Other proposed predictors, such as disease duration or timing of surgery, have not shown consistent prognostic value. Prolonged pharmacotherapy before percutaneous rhizotomy did not worsen outcomes (141), and no significant difference has been found between early and late microvascular decompression (27).

The clinical course of trigeminal neuralgia can vary among patients. Attacks may occur in clusters lasting weeks to months, followed by pain-free intervals lasting weeks to years. Over time, pain attacks may increase in frequency or become continuous, leading to chronic disability (112a).

The overall prognosis depends on the underlying etiology and the response to treatment. Classical trigeminal neuralgia often responds well to surgical decompression, whereas secondary forms associated with multiple sclerosis or structural lesions may have a more relapsing or bilateral course (41; 45). Spontaneous remission can occur but is uncommon. Chronic or recurrent pain may lead to cumulative disability and reduced quality of life if inadequately treated.

Complications

Most complications are related to treatment rather than the disease itself, including severe and disabling complications from surgical treatments like painful post-traumatic trigeminal neuropathy (85). A rare disorder known as trigeminal trophic syndrome presents with ulceration in the trigeminal territory due to sensory loss and self-mutilation behaviors (98). This condition has a female predominance, with trigeminal neuralgia (35.7%) and stroke (21.6%) being the most common antecedent disorders (69).

Another complication of trigeminal neuralgia is a status trigeminal neuralgia. This proposed severe and continuous form of trigeminal neuralgia presents as high-frequency or sub-continuous severe pain lasting more than 3 days with associated functional limitations, such as difficulty eating, hydrating, or communicating (146).

Psychological and social consequences are increasingly recognized. In one study, more than a third of patients reported suicidal ideation, and 2.6% reported self-injury (70). Anxiety, depression, and impaired quality of life are frequent comorbidities. Clinicians should routinely screen for psychiatric distress and provide appropriate mental health referrals.

Clinical vignette

A 70-year-old female presented to the neurology clinic for evaluation of facial pain. She reported pain in her left upper teeth starting 1 year ago, leading to tooth extraction with worsening pain. Over 3 months, the pain spread to involve her left cheek and chin. She had occasional pain in her left temple and would get mild redness in her left eye during these episodes. Pain was described as “someone taking a pen and running it through her face” and “electrical jolts.” She had difficulty chewing on that side and difficulty with her speech. Brain MRI demonstrated neurovascular conflict from the left superior cerebellar artery with evidence of trigeminal nerve hyperintensity. She was started on carbamazepine 200 mg twice daily with a 25% improvement but did not tolerate higher doses. Lamotrigine was added with minimal additional benefit. She underwent trigeminal microvascular decompression with complete pain relief lasting 2 years off medication but then had a recurrence of symptoms. She underwent GammaKnife radiosurgery with 50% pain relief. With the re-addition of carbamazepine 200 mg twice daily, she achieved significant, though incomplete, pain relief.

Biological basis

Etiology and pathogenesis

The pathophysiology of trigeminal neuralgia is not completely understood. There are several hypotheses, and the underlying pathophysiology depends on the type of trigeminal neuralgia. Rare genetic cases are also reported (57).

Neurovascular conflict from classical trigeminal neuralgia

Classical trigeminal neuralgia is thought to result from focal demyelination of trigeminal afferent fibers at the root entry zone of the pons, leading to ectopic and ephaptic discharges (39). The most common cause is vascular compression, usually by a tortuous loop of the superior cerebellar artery, although venous or other arterial contacts may also occur (41). High-resolution MRI frequently shows neurovascular contact of the trigeminal root, but such findings are common in asymptomatic individuals and are not diagnostic (44). A meta-analysis and subsequent prospective studies found that neurovascular contact is common and sensitive for trigeminal neuralgia but not specific (198). When neurovascular conflict is associated with nerve atrophy or displacement, both are highly specific for symptomatic disease (198). Compression of the trigeminal nerve at the root entry zone has a specificity of 100% (45).

Chronic compression produces focal demyelination and hyperexcitability of affected fibers, with altered expression of voltage-gated sodium channels and cross-talk (ephaptic communication) between adjacent axons (52; 162; 191; 110; 74; 39). The injury to the nerve may cause reactive oxygen species activating the TRPAV1 channels on the surface of trigeminal ganglion neurons based on animal models of trigeminal neuralgia (101; 61). Functional imaging demonstrates activation of the trigeminal nuclei, thalamus, and somatosensory cortex, as well as limbic regions involved in emotion and memory (121; 196). Central sensitization and gray matter or connectivity changes on MRI suggest that both peripheral and central mechanisms contribute to symptom persistence and severity (133; 187; 35; 111).

Secondary trigeminal neuralgia in the setting of multiple sclerosis

In secondary trigeminal neuralgia, demyelination can result from multiple sclerosis plaques involving the trigeminal root, accounting for the higher incidence of trigeminal neuralgia in patients with multiple sclerosis. A “double-crush” mechanism has been proposed, combining pontine demyelination with peripheral neurovascular compression (56).

Proposed theory for idiopathic trigeminal neuralgia

The underlying etiology of idiopathic trigeminal neuralgia is not known but is still thought to involve demyelination, likely near the root entry zone (22). Similar to classical trigeminal neuralgia, focal myelin injury can lower the firing threshold of trigeminal afferents and permit cross-activation between fibers, producing brief, high-frequency bursts that may continue after a stimulus and making light touch a common trigger. Other proposed mechanisms for idiopathic trigeminal neuralgia include trigeminal hyperexcitability from rare gain-of-function variants in voltage-gated sodium channel genes (reported mainly in small familial case series, with uncertain prevalence and clinical significance), as well as inflammatory processes or nonspecific brainstem lesions.

Pathophysiology of trigeminal neuropathy

Pathophysiological studies on this topic are extremely limited. Unlike trigeminal neuralgia, in which there is predominantly demyelination, painful trigeminal neuropathy likely involves predominant axonal loss (46).

Epidemiology

The epidemiology of trigeminal neuralgia is unclear as it is a rare disorder. Population studies have estimated a prevalence of less than 1% (114; 163; 123).

Classical trigeminal neuralgia

Classical trigeminal neuralgia is uncommon before the age of 40, and incidence rises with age, from 17.5 per 100,000 at the age of 60 to 25.6 per 100,000 at the age of 70 (12). The vast majority of trigeminal neuralgia presentations are due to neurovascular compression, with rates ranging from 70% to 89% (44). Rare pediatric presentations occur but represent fewer than 10% of cases (12). The condition is more common in females, with ratios of 2:1 to 3:1 (96; 113; 51). Familial occurrence is rare, estimated at 1% to 2% (12), though higher rates have been reported in specific families (87; 32; 63; 165).

Secondary trigeminal neuralgia

Approximately 15% of trigeminal neuralgia cases are attributed to secondary causes like a mass lesion or multiple sclerosis (44). In multiple sclerosis, onset occurs at a younger age (45), and risk is increased approximately 20-fold compared to the general population (41). Trigeminal neuralgia has been reported in 3.4% of patients with multiple sclerosis (89). Although idiopathic and classical forms are almost always unilateral (97%), multiple sclerosis–related trigeminal neuralgia is bilateral in up to 30% of cases (41). Trigeminal neuralgia secondary to multiple sclerosis is more common in females, with a prevalence of 2.4% in males and 3.8% in females (89). Beyond multiple sclerosis, lupus has been associated with a 2.84-fold increased risk of trigeminal neuralgia (173).

Trigeminal neuralgia has been reported in about 20% of patients with cerebellopontine angle tumors (109). Interestingly, trigeminal neuromas do not cause trigeminal neuralgia as they do not compress the nerve root (44).

Idiopathic trigeminal neuralgia

Idiopathic trigeminal neuralgia is thought to account for a minority of cases; however, its epidemiology has not been well described. Despite usually being considered the less common subtype, one Swedish study reported idiopathic trigeminal neuralgia in over two thirds of the population assessed (168). Otherwise, most studies report classical trigeminal neuralgia as being the predominant subtype, with idiopathic trigeminal neuralgia accounting for approximately 11% of cases (44). It likely shares similar demographic features with classical trigeminal neuralgia, including a female predominance and onset typically after the age of 40, but has been associated with a higher rate of medically refractory disease (03).

Painful trigeminal neuropathies

Painful trigeminal neuropathies collectively represent a smaller proportion of facial pain syndromes than trigeminal neuralgia. Postherpetic trigeminal neuralgia is the most common subtype, occurring in approximately 10% to 20% of patients with acute herpes zoster affecting the trigeminal nerve, particularly the ophthalmic division (44). The reported prevalence of painful post-traumatic trigeminal neuropathy ranges from 1.55% to 13% (140). Idiopathic painful trigeminal neuropathy is likely rare but has not been extensively studied.

Differential diagnosis

Confusing conditions: Orofacial and dental sources

Dental pain. Dental pain can present in a similar anatomical distribution as trigeminal neuralgia, especially in the early presentation of trigeminal neuralgia. One must exclude dental pain secondary to a structural cause or infection. Most dental pain is acute. Often, it is unilateral and located within the mouth. A cracked tooth usually presents as shooting pain when biting hard food, whereas dental caries or pulpitis pain often lasts minutes to hours, triggered by cold, heat, or sweetness (183). A lighted examination of the teeth, the attached gingiva, and the soft tissues of the oral mucosa typically elucidate a cause in these cases, such as a cracked tooth or a periodontal abscess. Diseases of the oral mucosa are painful and are often associated with lesions, such as lichen planus, herpes zoster, herpes simplex, or recurrent oral ulceration. Full details of the many causes of dental pain can be reviewed in the International Classification of Orofacial Pain (ICOP), first edition (09).

Unfortunately, many patients with trigeminal neuralgia are initially misdiagnosed as having a dental etiology, with one study finding that over half underwent an unnecessary tooth extraction (84). Out of 104 treated cases with trigeminal neuralgia, 88 patients were initially misdiagnosed and treated by dentists for dental pain. Among these patients, 55 patients were treated with dental extraction. Thirty-two were females, and 23 patients were males. The highest reported cases were found in the single tooth extraction category (27.3%) of the cases. The frequency of cases with multiple extractions decreases with increasing number of extracted teeth. The vast majority of the cases (92.7%) showed no response to dental extraction. Only four cases showed a moderate response to dental extraction. Mild response was not reported in this sample. There was no statistically significant relationship between the diagnosis and the number of extractions or between the diagnosis and the patient's role in the extraction decision.

Persistent idiopathic facial pain. Persistent idiopathic facial pain is a disorder characterized by daily recurrent non-neuralgiform facial or tooth pain that varies in intensity throughout the day. It has no associated neurologic deficits and does not follow a dermatomal pattern. Pain lasts for more than 2 hours per day for over 3 months. In many patients, the pain is constant. Pain onset is often associated with surgical or other dental or otolaryngological procedures, but many patients cannot recall the sequence of events leading to pain onset. Pain is described as dull, aching, or nagging. It is usually initially unilateral but can become bilateral (199). It can be triggered by stress or emotion with associated sharp exacerbations (23).

Temporomandibular disorders. Temporomandibular disorders can result in acute or chronic facial pain. Temporomandibular disorders can be further divided into myofascial orofacial and temporomandibular joint pain (09). The International Classification of Orofacial Pain further divides temporomandibular joint pain by its attributed causes, including arthritis or degenerative changes, joint displacement, and subluxation (09). An international consortium published the 2015 Diagnostic Criteria for Temporomandibular Disorders, which replaces the old Axis I/II system with a straightforward, dual‑component model that separates physical temporomandibular disorder diagnoses from assessment of pain‑related disability and psychosocial factors, making it easier to integrate temporomandibular disorder evaluation into routine neurologic practice (153). Chronic temporomandibular disorders are often associated with biological, social, environmental, emotional, and cognitive triggers (76). In the acute setting, temporomandibular disorders can occur after dental treatment or trauma. Pain occurs in the temporomandibular joint and surrounding muscles and ligaments, and it can radiate to the ear, temple, and neck. It is described as intermittent, dull, and achy pain, which can be acutely worsened by jaw movements. There can be pain-free periods as well. Patients have associated limited jaw opening, crepitus, clicking of the jaw, or muscle pain involving the neck and muscles of mastication. On physical examination, there can be reproducible tenderness to palpation of the temporomandibular joint. The symptoms can improve with a soft diet, analgesics, muscle relaxants, gabapentin, and benzodiazepines. Further treatment may depend on the underlying etiology. Refractory cases may require surgical evaluation.

Burning mouth syndrome. Burning mouth syndrome is defined by the International Classification of Orofacial Pain, first edition, as intraoral burning or dysesthesia recurring daily for more than 2 hours per day for more than 3 months, without any identifiable causative lesions, with or without somatosensory changes (09). Associated symptoms include subjective xerostomia, dysgeusia, bitter or metallic taste, sialorrhea, foreign body sensation, subjective change in color or tongue morphology, tingling, and itching (02). Patients can have extraoral symptoms, including ophthalmodynia, tinnitus, dizziness, abdominal pain, fibromyalgia, chronic fatigue syndrome, vulvodynia, and low back pain (119). Treatment includes symptomatic treatment with neuropathic pain medication (gabapentin, tricyclic antidepressants, cannabinoids), antidepressants, and lifestyle modification.

First-bite syndrome. First-bite syndrome is characterized by sharp or cramping pain in the parotid region that occurs with the first bite of each meal and improves with subsequent bites (167). It has been attributed to dysfunction in sympathetic and parasympathetic innervation of the parotid gland. It is most often seen after surgery to the parotid region but can also be seen in the setting of neoplasm. Patients can also have greater auricular neuropathy or Horner syndrome. Symptomatic treatment with botulinum toxin or neuropathic medication is sometimes required. Radiotherapy is sometimes used for cases after cervical lymph node dissection (106). Pain can resolve spontaneously.

Numb chin syndrome. Numb chin syndrome is the commonly used term for mental or inferior alveolar neuropathy, which presents as unilateral numbness, paresthesia, or pain of the chin (107; 19; 65; 16). This presentation is associated with a local metastasis. Multiple case reports and case series report it as an isolated or initial presentation of a malignancy (59; 13). Other reported etiologies include odontogenic processes, neuroinflammatory disease, diabetes, temporal arteritis, Lyme disease, stroke, and sickle cell disease (67; 148). Due to its association with malignancy, a thorough investigation is required (164).

Acute maxillary rhinosinusitis

The obstruction of sinus ostia causes sinusitis, and maxillary sinusitis is the most common (58). Acute maxillary rhinosinusitis can present with pain in a similar distribution to early trigeminal neuralgia. This is often secondary to an infection (viral, bacterial, or fungal) and can also occur secondary to a dental infection or a dental extraction procedure. Other presenting symptoms include purulent nasal secretions and discharge, cough, abnormal transillumination, and tenderness to palpation over the sinuses (58), unlike trigeminal neuralgia, in which mild autonomic symptoms may be seen. Pain is typically described as dull, heavy, or throbbing and located over the cheeks and upper teeth. Pain, in this case, would resolve after sinusitis treatment.

Sphenoid sinus disease

Disease of the sphenoid sinus can cause symptoms due to its close proximity to a number of structures, including cranial nerves (II, III, IV, V1, V2, and VI), the internal carotid artery, carotid sinus, pituitary gland, sphenopalatine ganglion, sphenopalatine artery, pterygoid canal, and dura mater (189). This can include infections, inflammation, tumors, and other conditions, including CSF leak, meningocele, and vascular lesions. It can present with headache, cranial nerve deficits, vision loss, diplopia, and pain or numbness in the distribution of the trigeminal nerve. It is diagnosed with imaging (CT or MRI) and endoscopic examination (71).

Salivary duct blockage

Blockage of the salivary ducts, such as by tumors, stones, or infections (including mumps, bacteria, actinomyces, and other mycobacteria), can also elicit pain at the site of the obstructed gland (134). The pain is intermittent and characteristically occurs just before eating, when saliva would be excreted (185). The involved salivary gland may have associated tenderness and swelling, and xerostomia may be present. Examination requires observing the glands and the mouth and palpating the affected glands, as a stone may be palpable. Pain occurs due to gland swelling, which can be acute or chronic. Imaging, including ultrasound and CT, may be helpful to identify the extent of infection and evaluate anatomy. Treatment includes treating underlying infections, tumor removal, and use of sialagogues. In some cases, referral to an oral or maxillofacial surgeon is required for further management.

Trigeminal autonomic cephalgias

Trigeminal autonomic cephalgias are a group of disorders characterized by unilateral pain with lateralized, ipsilateral cranial parasympathetic autonomic features (85). Two trigeminal autonomic cephalgias, both subcategories of short-lasting unilateral neuralgiform headache attacks, are characterized by short episodes of pain that may be mistaken for trigeminal neuralgia: short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA). These can be episodic (attacks occurring in periods lasting 7 days to 1 year, separated by pain-free periods of at least 3 months) or chronic (attacks occurring for more than 1 year without remission or with pain-free periods lasting fewer than 3 months). Attacks can last 1 to 600 seconds, occurring as single or a series of stabs, and can occur in a saw-tooth pattern. Other trigeminal autonomic cephalgias include cluster headaches, in which attacks can last 15 to 180 minutes, and paroxysmal hemicrania, in which attacks can last 2 to 30 minutes. Parasympathetic autonomic symptoms are prominent in trigeminal autonomic cephalgias and can include conjunctival injection and lacrimation, nasal congestion and rhinorrhea, eyelid edema, forehead and facial sweating, miosis, and ptosis. By comparison, trigeminal neuralgia may have no or only mild cranial autonomic symptoms like lacrimation without conjunctival injection (139; 174). Unlike trigeminal neuralgia, pain episodes in SUNCT and SUNA can be triggered without a refractory period. Pain attacks are typically distributed in the V1 > V2 distributions (85). SUNCT/SUNA and trigeminal neuralgia can be difficult to differentiate and may even overlap, requiring both diagnoses.

Migraine

Migraine is a primary headache disorder attributed to nerve dysfunction leading to involvement of the trigeminovascular system through the release of neuropeptides like calcitonin gene-related peptide. There are four phases, including prodrome, aura (which may or may not be present), migraine attack (headache phase), and postdrome. Migraine attacks classically present with moderate to severe unilateral throbbing headache associated with nausea, photophobia, and phonophobia and worsens with activity. Attacks last 4 to 72 hours. Facial pain is uncommon in migraine but, when present, typically occurs in the V2 or V3 distribution (157). One cohort study from Taiwan concluded that migraine could be a risk factor for the development of trigeminal neuralgia as there was a higher incidence of trigeminal neuralgia in the migraine cohort than the control cohort (108).

Glossopharyngeal neuralgia

Glossopharyngeal neuralgia causes pain in the distribution of the ninth trigeminal nerve (angle of jaw, ear, tonsillar fossa, base of tongue). Given the location of the pain, trigeminal neuralgia, involving especially the mandibular branch, can be confused with glossopharyngeal neuralgia. Most often, glossopharyngeal neuralgia is idiopathic, but it can be secondarily caused by vascular compression, demyelination, inflammatory and autoimmune disease (eg, Sjogren disease), intraoral and peritonsillar infections, space-occupying lesions, Eagle syndrome (styloid process elongation or stylohyoid ligament ossification), and oropharyngeal cancers (161). Like trigeminal neuralgia, pain with glossopharyngeal neuralgia is sharp, stabbing, or electrical shock-like and lasts seconds to minutes, with abrupt onset and resolution. Swallowing can provoke the pain (156). Glossopharyngeal neuralgia can be associated with vagal symptoms like coughing, hoarseness, bradycardia, and even syncope (85). Glossopharyngeal neuralgia has been reported to co-occur with trigeminal neuralgia with an odds ratio of 60.60 for the association between neurovascular compression disorders like glossopharyngeal neuralgia and trigeminal neuralgia (173).

Nervus intermedius neuralgia

Nervus intermedia neuralgia (also known as geniculate neuralgia) causes deep ear pain in the distribution of the nervus intermedius (also known as the geniculate nerve), which is a tiny branch of the facial nerve (149). In the literature, nervus intermedius neuralgia has quite variable radiation that can overlap with the distribution of the trigeminal, glossopharyngeal, and occipital nerves; concurrent neuralgias have even been reported. The pain should be severe, sharp, shooting, or stabbing, lasting seconds to minutes with a periauricular or external ear canal trigger area (85).

Tolosa Hunt syndrome

Tolosa Hunt syndrome is a condition of granulomatous inflammation of the cavernous sinus, superior orbital fissure, or orbit seen on MRI or biopsy, leading to paresis of one or more of the ipsilateral third, fourth, and or sixth cranial nerves (85). Symptoms include orbital or periorbital pain, diplopia, and ptosis (99). The optic and trigeminal nerves can be involved. Diagnosis is made using MRI or biopsy, and inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) may be elevated. Treatment is with high-dose intravenous steroids.

Paratrigeminal oculosympathetic syndrome

Paratrigeminal oculosympathetic syndrome (also known as Raeder syndrome) involves the trigeminal and oculosympathetic nerves, leading to ipsilateral pain, sensory loss, miosis, or ptosis with intact sweating (no anhidrosis) (78). It is caused by lesions in the middle cranial fossa, where the internal carotid artery lies, and the internal carotid nerve, containing postganglionic sympathetic nerve fibers, runs alongside the artery before dividing to form the carotid plexus.

Table 1. A Comparison of Trigeminal Neuralgia and Other Similarly Presenting Conditions

Etiology	Pain Sensation	Pain Distribution	Pain Duration	Associated Symptoms
Trigeminal neuralgia	Electric shock, shooting, stabbing, or sharp	Trigeminal nerve distribution (V2> V3> V1)	Seconds to 2 minutes ± concomitant continuous pain	No or mild autonomic symptoms (eg, lacrimation)
Painful trigeminal neuropathy	Burning	Trigeminal nerve distribution	Paroxysmal or constant	Numbness or tingling, itching, allodynia
Dental pain	Acute, sharp	Around the affected tooth, may have radiation	Continuous with short triggered exacerbations	Presence of cracked tooth, dental abscess
Acute maxillary rhinosinusitis	Dull, achy, throbbing	Cheeks, upper teeth	Continuous	Fever, anosmia, purulent discharge
Sphenoid sinus disease	Dependent on the structures involved	Holocephalic, face, trigeminal nerve distribution if nerves involved	Continuous	Cranial nerve deficits, vision loss, diplopia, pain or numbness in trigeminal nerve distribution
Temporomandibular joint disorders	Dull, aching, muscle tightness	Temporomandibular joint, angle of mandible, radiation to ear, temple, neck	Minutes to hours	Jaw-clenching, teeth grinding
Salivary duct blockage	Dull, aching	Site of blocked duct	Minutes	Xerostomia, gland swelling
Trigeminal autonomic cephalgias (SUNCT, SUNA)	Sharp	V1>V2	1 to 600 seconds	Parasympathetic autonomic symptoms
Migraine	Classically throbbing,	Classically unilateral head or neck	4 to 72 hours	Nausea, vomiting, photophobia, phonophobia, aura
Glossopharyngeal neuralgia	Electric shock-like, shooting, stabbing, or sharp	Angle of jaw, ear, tonsillar fossa, base of tongue	Seconds to 2 minutes	Vagal symptoms
Nervus intermedius neuralgia	Shooting, stabbing, or sharp	Deep ear	Seconds to minutes
Persistent idiopathic facial pain	Dull, aching, nagging	Unilateral or bilateral, deep, no specific distribution	Hours occurring daily	No neurologic deficits
Tolosa Hunt syndrome	Dull aching pain	Periorbital	Minutes, occurring with eye movement	Periorbital pain, diplopia, ptosis
Paratrigeminal oculosympathetic syndrome	Neuralgiform or numbness	Trigeminal nerve distribution		Ipsilateral miosis and ptosis, intact sweating
Burning mouth syndrome	Burning pain	Intraoral	Daily for longer than 2 hours	Dysgeusia, sialorrhea, foreign body sensation, mood disorders

Associated or underlying disorders

Classical trigeminal neuralgia. Classical trigeminal neuralgia is caused most often by neurovascular compression, typically by a redundant or tortuous loop of the superior cerebellar artery. Other arteries that can be involved include the anterior inferior cerebellar artery, the posterior inferior cerebellar artery, vertebral artery, basilar artery, labyrinthine artery, and other unspecified small arteries. (18; 41). Veins can also compress the trigeminal nerve, including the superior petrosal vein and its tributaries: transverse pontine, pontotrigeminal, cerebellopontine fissure, and middle cerebellar peduncle (175).

Secondary trigeminal neuralgia.

• Multiple sclerosis
• Cerebellopontine angle mass lesion, such as a meningioma or schwannoma
• Vascular malformation like an arteriovenous malformation

Painful trigeminal neuropathy.

• Acute herpes zoster infection
• Post-herpetic neuralgia
• Post-traumatic trigeminal neuropathy (mechanical, chemical, thermal, or radiation, including iatrogenic from neuroablative procedures)
• Other reported causes include multiple sclerosis, space-occupying lesions, connective tissue disorder, hereditary disorder, or other systemic disorders

Diagnostic workup

Step 1: History

Trigeminal neuralgia. To diagnose trigeminal neuralgia, the pain should be unilateral in the distribution of the trigeminal nerve with sharp/electrical paroxysms of pain. If this statement is not true, then the diagnosis is unlikely to be trigeminal neuralgia. Constant background pain is allowed, but there must be the overlying paroxysms of pain. Note that rare cases of trigeminal neuralgia have been reported, especially in patients with trigeminal neuralgia.

Trigeminal neuropathy. If there are no paroxysms, but burning pain or numbness and tingling is present, then the diagnosis may instead be trigeminal neuropathy.

Short-lasting unilateral neuralgiform headache attacks (SUNHAs). Consider one of the SUNHAs if there is predominantly V1 distribution with prominent autonomic symptoms.

Persistent idiopathic facial pain (PIFP). If there are no paroxysms and the pain is achy not following a trigeminal distribution, then the likely diagnosis if PIFP.

Step 2: Physical exam

Numbness. Assess for an objective sensory deficit (numbness) in the V1 to V3 territory, which would be consistent with trigeminal neuropathy.

Trigger zones versus allodynia or hypalgesia. Trigger zones are common in trigeminal neuralgia, whereas there may be more diffuse allodynia or hyperalgesia in trigeminal neuropathy.

Autonomic signs. Look for prominent unilateral cranial autonomic symptoms, which are most consistent with trigeminal autonomic cephalalgias.

Temporomandibular joint / dental exam. Evaluate the jaw and mouth for alternative causes like temporomandibular joint disorder, a cracked tooth, etc.

Step 3: Investigations

MRI brain. 3D heavily T2-weighted MRI sequences with thin cuts through the course of the trigeminal nerve are highly recommended in all patients with trigeminal neuralgia.

Steady-state free precession sequences (such as constructive interference steady state [CISS] from Siemens, and fast imaging employing steady-state acquisition [FIESTA] from GE Healthcare) are helpful as they can help to distinguish soft tissue from CSF, resulting in better imaging of the trigeminal nerve and adjacent vessels (90; 31). These investigations may identify a cause in up to 15% of patients.

MR angiogram (MRA). MRA of the head, complementary to high-resolution structural imaging, can further evaluate vascular etiologies and is helpful in surgical treatment planning for microvascular decompression (171). Preoperative magnetic resonance tomographic angiography has been suggested as useful in patient selection and outcome prediction for microvascular decompression surgery (182).

Contraindication to MRI. If there is a contraindication to MRI, trigeminal reflexes or evoked potentials can be considered (21). Evoked potentials, quantitative sensory testing, and electrophysiological studies can also help detect symptomatic trigeminal neuralgia, but more research is needed before these studies can be routinely recommended.

One study showed that an ipsilateral prolonged latency (> 0.5 ms) compared to unaffected side was predictive of classical trigeminal neuralgia (50). Another study found that the blink reflex test showed high specificity (87.5%) for detecting neurovascular compression in classical trigeminal neuralgia (28).

Management

Treatment for trigeminal neuralgia is multidisciplinary and can include medication and surgery.

First-line treatment
	• Carbamazepine 200 to 1800 mg per day
	• Oxcarbazepine 300 to 2700 mg per day
Second-line treatment for alternative or adjunctive treatment
	• Baclofen
	• Gabapentin
	• Lamotrigine
	• OnabotulinumtoxinA
	• Pregabalin
Acute treatments for exacerbations
	• Intranasal lidocaine
	• Intravenous fosphenytoin
	• Intravenous lacosamide
	• Intravenous lidocaine
	• Intravenous phenytoin
	• Trigeminal nerve blocks
Microvascular decompression
	• Indicated for medically refractory classic trigeminal neuralgia
Neuroablative techniques
	• These options are typically used in cases other than classic trigeminal neuralgia or in classic trigeminal neuralgia when microvascular decompression is not feasible.
	• Radiosurgical techniques: Gamma Knife and CyberKnife are indicated for medically refractory trigeminal neuralgia.
	• Percutaneous techniques: Percutaneous techniques, including balloon compression, glycerol rhizotomy, and radiofrequency thermocoagulation, are indicated for medically refractory trigeminal neuralgia.
Multidisciplinary care
	• Other team members that may be important to care include pain psychology/psychiatry, dentistry, and speech language pathology.
Treatments under investigation
	• Medications: vixotrigine and basimglurant
	• Neuromodulation: transcranial magnetic stimulation and transcranial direct current stimulation

Sodium channel blockers

Carbamazepine. Carbamazepine is considered the gold standard of treatment with level A evidence, and it is the only FDA-approved therapy for trigeminal neuralgia (68; U.S. Food and Drug Administration 2023). The starting dose is 200 to 400 mg, and an increase up to 200 to 1800 mg per day is recommended (80; 21; 22). Dosing is split over two to four doses per day.

Oxcarbazepine. Oxcarbazepine is a structural analog to carbamazepine and shares a similar mechanism of action (voltage-gated sodium channel blockade), but it is metabolized differently (01). It has similar efficacy to carbamazepine with level B evidence (80; 21). A starting dosage of 300 to 600 mg increased up to 300 to 2700 mg per day is recommended (22). Dosing is split over two to four doses per day.

Adverse effects. The clinical utility of these medications may be limited by their side effect profile. Carbamazepine can cause hyponatremia, drowsiness, rash, liver damage, ataxia, and potential drug interactions. Oxcarbazepine may have fewer side effects except hyponatremia. They have been found to be less tolerated in females (26). Start with low doses and titrate slowly according to tolerance, especially in older patients. Testing for HLA B1502 allele is also recommended in patients of Asian descent as there is an increased risk of developing Stevens-Johnson syndrome or toxic epidermal necrosis with this allele. This has been attributed to the Han Chinese population, but the allele is frequently seen in many other Asian populations (68).

Second-line treatments

Second-line or add-on pharmacotherapy for trigeminal neuralgia includes lamotrigine, baclofen, gabapentin, pregabalin, phenytoin, and onabotulinumtoxinA. These can be used in place of carbamazepine or oxcarbazepine if poorly tolerated, or they can be used in addition to them if symptom control is inadequate (80; 22).

Lamotrigine. Lamotrigine has level C evidence for use in trigeminal neuralgia (80). A starting dose of 25 mg daily, up to a maximum dose of 100 to 400 mg total daily dose, is recommended. Dosing is split over two daily doses (22). Slow titration while monitoring for rash is required due to the risk of Stevens-Johnson syndrome.

Baclofen. Baclofen has level C evidence for use in trigeminal neuralgia (80). A starting dose of 10 mg up to a maximum dose of 15 to 70 mg per day is recommended. Dosing is split over three daily doses (22). Baclofen efficacy is often limited by adverse effects preventing optimal dosing.

Gabapentinoids. Gabapentin has low-quality evidence for use in trigeminal neuralgia but can be considered as second-line or add-on therapy (80). A starting dose of 300 mg up to a maximum of 600 to 3600 mg daily is recommended. Dosing is split over three daily doses (22). Pregabalin has some efficacy in trigeminal neuralgia, but evidence is limited (22).

OnabotulinumtoxinA. OnabotulinumtoxinA has been shown to have efficacy in trigeminal neuralgia. One systematic review found that doses ranging from 25 to 100 U were effective in reducing pain severity and frequency by 50%. As overall evidence is weak, it is recommended as an add-on therapy (22). However, a 2024 systematic review reported that response rates ranged between 51.4% and 100%, similar to the reported response rate range for carbamazepine (56% to 90.5%) (128).

Other. Lacosamide has been studied in medical refractory trigeminal neuralgia using an initial daily lacosamide dose of 100 mg (range: 50–400) titrating to a maintenance daily dose of 200 mg (range: 50–600) (126; 127). Pain relief from lacosamide was seen in two thirds of patients. A case series with six patients looked at the use of erenumab in patients with trigeminal neuralgia and concurrent migraine, with five reporting trigeminal neuralgia benefit (95). Similarly, a retrospective analysis of 10 patients with trigeminal neuralgia on erenumab found that 90% (9 of 10) improved on the numerical rating scale (138). Phenytoin has some efficacy in trigeminal neuralgia, but evidence is limited (22).

New potential pharmacologic options

Vixotrigine. Vixotrigine is a selective Nav1.7 sodium channel blocker that failed to meet its primary endpoint in a phase 2a trial for trigeminal neuralgia (195). Although this trigeminal neuralgia trial was not positive, the phase 2 trial for small fiber neuropathy was positive (66). There are no updates on vixotrigine for trigeminal neuralgia at this time.

Basimglurant. A phase II/III randomized controlled trial is underway for basimglurant, a metabotropic glutamate receptor 5 (mGluR5) inhibitor, as a treatment for trigeminal neuralgia (NCT05217628). No results have been published on clinicaltrial.gov at this time to provide an update.

Acute pharmacologic management

Management of trigeminal neuralgia typically focuses on chronic disease management, but patients can present in crisis needing acute treatment. Retrospective analysis of acute management in the emergency department found that nearly three quarters are treated with opioids (145). A systematic review of 17 studies discussed various acute options, including nerve blocks, sumatriptan nasal/subcutaneous, lidocaine for oral/nasal mucosa, and infusions (122). Other intravenous considerations include valproic acid, lidocaine, and clonazepam, but more research is needed (160).

Intranasal lidocaine. A randomized controlled trial of intranasal lidocaine 8% compared to nasal saline demonstrated a significant reduction in pain lasting for patients with trigeminal neuralgia affecting the V2 distribution (94). Other publications have looked at similar methods, including an observational study using a commercial device intranasally for a sphenopalatine ganglion nerve block with 2% lidocaine and a case report using 1% atomized intranasal lidocaine (60; 135). Common adverse effects include stinging, burning, numbness of nose or eyes, bitter taste, and throat numbness (94).

Intravenous lidocaine. Several studies have reported benefit with the use of intravenous lidocaine for an acute exacerbation of trigeminal neuralgia (37; 124; 120). A 2025 retrospective case series (n=20) of intravenous lidocaine demonstrated that 80% achieved adequate control, 5% achieved near resolution, and 15% had no response (120). Of those responders, 45% had a 6-month sustained response. No side effects were reported. One randomized controlled trial reported the use of intravenous lidocaine more prophylactically as 4 weekly sessions (166). A similar approach was used in a case series in which intravenous lidocaine and magnesium were used for medically refractory trigeminal neuralgia (10).

Intravenous fosphenytoin. Multiple observational cases and studies have reported that intravenous fosphenytoin can be used to manage acute crises in trigeminal neuralgia (42; 154; 131; 08; 20; 130). Dosing ranged widely between studies, with one using a loading dose ranging between 9.8 and 20.7 mg/kg and a maintenance dose range of 7.5 to 9.5 mg/kg (130). Another study used 20 mg PE/Kg as a loading dose, then initiated oral phenytoin 5 mg/kg/day (08). Commonly reported side effects include hypotension, dizziness, nausea, nystagmus, incoordination, and sedation (154; 08).

Intravenous lacosamide. One study found that intravenous lacosamide effectively reduced pain in acute exacerbations in a cohort of 121 patients when compared to intravenous phenytoin (125). Lacosamide had lower readmission rates and more sustained pain relief.

Intravenous phenytoin. Intravenous phenytoin has also been used to treat acute exacerbations of trigeminal neuralgia (154; 125). More adverse effects were seen with phenytoin administration when compared to lacosamide infusions (125).

Nerve blocks. The use of nerve blocks for refractory disease or as acute treatment has reported benefit, but response tends to be short- to medium-term (83; 144; 17; 91; 11). Local anesthetics with or without steroids have been reported. One study specifically noted a lack of response to occipital nerve blocks (64). There are case reports as well as a prospective observational study (n=15) in which the use of sphenopalatine ganglion blocks was effective for trigeminal neuralgia (116; 129; 135).

Surgical management

For long-term cases refractory to pharmacotherapy and in which there is a clear structural abnormality on neuroimaging, more aggressive interventional techniques are warranted. Microvascular decompression is the gold standard treatment but is only indicated for classic trigeminal neuralgia. Stereotactic radiosurgery is a noninvasive treatment modality that is more effective than microvascular decompression but can be used in classic, secondary, or idiopathic trigeminal neuralgia. Other neuroablative options include percutaneous treatments like balloon compression, glycerol rhizotomy, and radiofrequency thermocoagulation (40).

Microvascular decompression

Microvascular decompression addresses trigeminal neuralgia by relieving neurovascular compression at the trigeminal root, with the intent to preserve the nerve (152). In surgical series, initial pain relief is high, and classic long-term data report about 70% pain freedom without medication at 10 years (18). In contemporary cohorts, major complications remain uncommon but clinically important, including posterior fossa hemorrhage or infarct, infection, hearing loss, facial numbness, and CSF leak, with one series reporting 0% mortality and major complications in 8.2% (152; 86; 54).

Outcomes appear best in carefully selected patients with a classical phenotype and supportive clinical and imaging features. A 5-year prospective observational cohort found higher medication-free pain freedom after microvascular decompression than with medical management alone (with the expected caveat of selection bias in nonrandomized comparisons), and a preoperative scoring update emphasizes factors such as age greater than 45 years, carbamazepine response, and evidence of neurovascular compression in predicting longer-term outcomes (177; 188). When pain recurs, repeat microvascular decompression can be effective. A systematic review supports feasibility, and a 2025 meta-analysis of second-line strategies suggests that neurolysis during re-exploration may be associated with improved outcomes, balanced against sensory risks (93; 15). In retreatment after prior microvascular decompression, percutaneous rhizotomy tends to produce more sensory morbidity than repeat microvascular decompression or stereotactic radiosurgery, which is a key counseling point when selecting second-line procedures (15).

Not all patients are candidates for microvascular decompression, particularly when there is no clear neurovascular conflict or after prior microvascular decompression, in which case radiosurgery or percutaneous ablative procedures are often considered (36). In trigeminal neuralgia associated with multiple sclerosis, microvascular decompression may still provide meaningful benefit, especially when neurovascular conflict is present. When conflict is absent, other procedures (eg, percutaneous balloon compression or stereotactic radiosurgery) may be preferred (117; 81). For patients without neurovascular conflict in whom microvascular decompression is not indicated, microsurgical internal neurolysis (nerve combing) is an alternative, with generally favorable pain outcomes but a substantial risk of numbness (105).

Stereotactic radiosurgery

Stereotactic radiosurgery is a noninvasive outpatient option that targets the trigeminal root entry zone with a focused radiation dose. The two most commonly used platforms differ mainly in radiation source and immobilization. Gamma Knife uses cobalt-based gamma radiation with a rigid head frame (158; 06), whereas CyberKnife uses a robotic linear accelerator with image guidance to track the target and does not require a rigid frame (150).

Gamma Knife. Gamma Knife radiosurgery delivers a high dose (70 to 90 Gy) to the trigeminal root entry zone, producing a delayed axonal lesioning effect that interrupts pain transmission (158; 06). Compared with microvascular decompression, it is generally less effective with higher recurrence but has a lower complication rate (04). In the 2008 AAN/EFNS review, 69% of patients were pain-free at 1 year and 52% at 3 years, and onset of pain relief may be delayed by about a month (80). Adverse effects include facial numbness and sensory disturbance, which can emerge months after treatment (06). Predictors of poorer response reported in recent cohorts include hyperglycemia, lack of neurovascular compression, poor response to carbamazepine, concomitant continuous pain, and atypical pain features (62; 184). Gamma Knife can also be used as a salvage option after recurrent pain following microvascular decompression, although repeat radiosurgery increases the risk of sensory complications, with one study reporting numbness in nearly two thirds after repeat treatment (88; 155). Rarely, neuroablative procedures, including stereotactic radiosurgery, can lead to post-traumatic painful trigeminal neuropathy (85).

CyberKnife. CyberKnife is another stereotactic radiosurgery platform used for medication-refractory trigeminal neuralgia. Because it uses a robotic linear accelerator with real-time image guidance, it can be delivered without a rigid frame and has been used in repeat treatment settings; however, repeated treatments can increase sensory complications (150). Long-term benefit has been reported in observational series, including follow-up out to 13 years in one review (25). A 2025 systematic review and meta-analysis evaluating repeat stereotactic radiosurgery across platforms (Gamma Knife and CyberKnife) reported improvement in just under three quarters after a second treatment, but with high complication rates (including trigeminal nerve dysfunction) and frequent recurrence within 2 years (181).

Percutaneous techniques

Percutaneous procedures are minimally invasive, needle-based, ablative options that create a controlled injury to the trigeminal ganglion or root to reduce pain transmission. This distinguishes them from microvascular decompression, which relieves neurovascular conflict without intentionally damaging the nerve, and from stereotactic radiosurgery, which produces a delayed lesion effect through focused radiation rather than a percutaneous lesion. Percutaneous techniques are typically brief and can provide rapid relief, but recurrence is common over time (40). Neuroablative procedures can lead to new neuropathic facial pain, which the ICHD-3 classifies as post-traumatic painful trigeminal neuropathy (85), previously known as anesthesia dolorosa.

The main percutaneous options are balloon compression, glycerol rhizotomy, and radiofrequency thermocoagulation. Balloon compression inflates a balloon in Meckel’s cave to compress the trigeminal ganglion and is generally performed under general anesthesia. Published series report high early pain control with declining durability over years (40; 36). Glycerol rhizotomy offers similar early pain relief but may have higher complication rates in some series, and radiofrequency thermocoagulation can provide excellent immediate pain control with long-term recurrence in a substantial proportion (40). Because these are ablative approaches, they are often considered in patients who are poor candidates for craniotomy and who lack neurovascular compression, or they may be used in secondary trigeminal neuralgia, including multiple sclerosis (36; 82).

Patient selection matters. Preexisting sensory loss (numbness) should prompt reconsideration because it suggests painful trigeminal neuropathy and may increase the risk of iatrogenic post-traumatic painful trigeminal neuropathy after further nerve injury (36). A 2025 systematic review comparing rhizotomy and radiosurgery suggested rhizotomy tends to provide more immediate relief, whereas radiosurgery may have more durable benefit with fewer adverse effects (97). Other reported adverse effects include diminished corneal reflex, masseter weakness and paralysis, dysesthesia, keratitis, and CSF leak (36).

Neuromodulatory techniques. Neuromodulatory techniques are an ongoing area of interest in trigeminal neuralgia, though available data remain sparse.

Transcranial magnetic stimulation is a noninvasive technique in which an electromagnetic coil is used to create a magnetic field, stimulating the brain cortex during brief magnetic pulses to changes in cortical excitability (192). It has been studied in several neuropathic pain conditions, but there is insufficient evidence to determine its efficacy in trigeminal neuralgia. Transcranial direct current stimulation has been studied in trigeminal neuralgia, and preliminary evidence shows that it may effectively alleviate trigeminal neuralgia pain (14).

Multidisciplinary care

Given the significant psychosocial impact of trigeminal neuralgia, a multifaceted treatment approach involving referrals to psychology or psychiatry and speech or swallow therapies as warranted is highly recommended. Dental care is an important consideration, as many patients with orofacial pain avoid routine maintenance of oral health due to pain concerns (100). The dental team should understand the patient’s pain condition, appointments should be scheduled during times of lowest pain intensity or symptom remission, and procedures should minimize pain stimuli, such as using soft brushes or sponges soaked in chlorhexidine and taking the least invasive approach possible. Local anesthesia can exacerbate pain. Communication between the patient and dental team is important to understand trigger zones and each patient’s specific symptoms (118).

Outcomes

Trigeminal neuralgia often follows a relapsing course, with flares lasting weeks to months and remissions that can last weeks to years; some patients develop persistent background pain between paroxysms (112). Most patients experience substantial improvement in pain-related quality of life when attacks are controlled. Outcomes depend largely on treatment modality. Patient-reported tools such as the Barrow Neurological Institute (BNI) Pain and Numbness Scales and the Visual Analog Scale (VAS) are commonly used to assess treatment response and residual sensory symptoms (38; 193). Microvascular decompression generally provides the most durable pain freedom in appropriate surgical candidates, with classic long-term data showing about 70% pain-free at 10 years (18). Stereotactic radiosurgery is less invasive, but pain relief is often delayed, and sensory disturbance is the most common adverse effect (179; 190). For recurrent pain, retreatment with repeat microvascular decompression or repeat radiosurgery can be considered in selected patients, but sensory complications are more likely after repeat or more extensive lesioning (44; 142; 21; 93). Across neuroablative procedures (percutaneous lesioning and radiosurgery), new neuropathic facial pain with sensory loss or allodynia can occur and is classified in the ICHD-3 as painful post-traumatic trigeminal neuropathy (85).

Special considerations

Psychosocial impact. Screen for anxiety/depression and pain catastrophizing. Consider referral to pain psychology/psychiatry when distress, avoidance, or functional impairment is prominent.

Dental care. Many patients avoid routine dental hygiene. Encourage preventive care and proactive communication with dentistry about trigger zones. Schedule visits during lower-symptom periods and minimize noxious stimulation when possible (100; 118).

Procedural counseling. Before neuroablative procedures (stereotactic radiosurgery or percutaneous lesioning), counsel explicitly about the possibility of persistent sensory loss and iatrogenic neuropathic facial pain, which the ICHD-3 classifies as painful post-traumatic trigeminal neuropathy (85).

Herpes zoster ophthalmicus. If facial pain is due to acute zoster, treat promptly with antiviral therapy and involve ophthalmology when V1 is affected or ocular symptoms are present (186; 77).

Pregnancy

General principle. Management is individualized and ideally coordinated with obstetrics and maternal fetal medicine. Try to minimize fetal drug exposure while still controlling severe pain (functional impairment, weight loss from eating triggers, sleep deprivation).

Antiseizure medications. The use of antiseizure medications during pregnancy increases the risk of major congenital malformations like neural tube defects, but lamotrigine and oxcarbazepine are among those with the lowest risk (137). In particular, antiseizure medication polypharmacy has also been associated with risk of autism and intellectual disability (115). Serum concentrations, especially for lamotrigine, can decrease during pregnancy. If used, prescribe the lowest effective dose and folic acid 0.4 mg supplementation per obstetric guidance (137).

OnabotulinumtoxinA. Based on a large retrospective analysis over 29 years, the risk of major congenital malformations is no different than baseline risk (33). Data specific to use in trigeminal neuralgia are limited, but there is minimal systemic absorption (172).

Local options. Local options are often preferred.

Peripheral nerve blocks with lidocaine. Lidocaine has reassuring human data and is commonly used in pregnancy when indicated.

Intranasal lidocaine. Although not performed in pregnant patients, there is a single randomized controlled trial on the use of intranasal lidocaine for trigeminal neuralgia (94).

Sphenopalatine ganglion block. Safety in pregnancy is limited to case-level reports (79), but it can be considered when needed.

Topical lidocaine. Systemic absorption is low, so topical lidocaine (eg, 5% patch) could be considered as it has been found to be effective in trigeminal neuralgia and postherpetic neuralgia (29; 194; 197).

Procedures

Surgery and radiation-based procedures are usually deferred, if possible, if a fluoroscopy-guided percutaneous procedure is unavoidable (19).

Minimize fetal dose (shielding, shortest fluoroscopy time). Doses under 100 mGy could be considered after 15 weeks’ gestational age (169), but no dose is absolutely risk free.

References

01: Abou-Khalil BW. Oxcarbazepine and carbamazepine: expected and unexpected differences and similarities. Epilepsy Curr 2007;7(3):74-6. PMID 17520080
02: Adamo D, Spagnuolo G. Burning mouth syndrome: an overview and future perspectives. Int J Environ Res Public Health 2022;20(1):682. PMID 36613002
03: Akkara Y, Thakrar P, Ahmed M, et al. Incidence, role, and imaging-based diagnostic accuracy of neurovascular compression in trigeminal neuralgia: a longitudinal cohort study. Br J Neurosurg 2026;40(2):313-20. PMID 40910937
04: Alizadeh Y, Hayak H, Khoshnevisan A. Microvascular decompression versus Gamma Knife surgery in patients with drug-resistant trigeminal neuralgia: a systematic review and meta-analysis. World Neurosurg 2022;167:67-73. PMID 35970291
05: Allam AK, Sharma H, Larkin MB, Viswanathan A. Trigeminal neuralgia: diagnosis and treatment. Neurol Clin 2023;41(1):107-21.** PMID 36400550
06: Al-Quliti KW. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh) 2015;20(2):107-14. PMID 25864062
07: Ameli NO. Avicenna and trigeminal neuralgia. J Neurol Sci 1965;2(2):105-7. PMID 4862205
08: Andersen ASS, Heinskou TB, Asghar MS, et al. Intravenous fosphenytoin as treatment for acute exacerbation of trigeminal neuralgia: a prospective systematic study of 15 patients. Cephalalgia 2022;42(11-12):1138-47. PMID 35469443
09: Anonymous. International Classification of Orofacial Pain. 1st edition. Cephalalgia 2020;40(2):129-221.** PMID 32103673
10: Arai YCP, Hatakeyama N, Nishihara M, Ikeuchi M, Kurisuno M, Ikemoto T. Intravenous lidocaine and magnesium for management of intractable trigeminal neuralgia: a case series of nine patients. J Anesth 2013;27(6):960-2. PMID 23712613
11: Aranha RLB, Resende RG, de Souza FA. Peripheral nerve blocks for acute trigeminal neuralgia involving maxillary and mandibular branches: a case report. J Dent Anesth Pain Med 2023;23(6):357-62. PMID 38076503
12: Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal neuralgia: basic and clinical aspects. Curr Neuropharmacol 2020;18(2):109-19. PMID 31608834
13: Assaf AT, Jürgens TP, Benecke AW, et al. Numb chin syndrome: a rare and often overlooked symptom. J Oral Facial Pain Headache 2014;28(1):80-90. PMID 24482791
14: Babakhani B, Tabatabaei NH, Elisevich K, et al. A preliminary study of the efficacy of transcranial direct current stimulation in trigeminal neuralgia. Front Hum Neurosci 2022;16:848347. PMID 35308616
15: Baig Mirza A, Fayez F, Georgiannakis A, et al. Recurrent trigeminal neuralgia following MVD: a meta-analysis of second-line treatment strategies. Neurosurg Focus 2025;59(3):E16. PMID 40889405
16: Balamurugan N, Arathisenthil SV, Senthilkumaran S, Thirumalaikolundusubramanian P. Numb chin syndrome: a harbinger of tumor progression or relapse. Am J Emerg Med 2017;35(5):805.e1-805.e2. PMID 28041759
17: Balta S, Koknel Talu G. Clinical effectiveness of peripheral nerve blocks with lidocaine and corticosteroid in patients with trigeminal neuralgia. Agri 2021 Oct;33(4):237-242. English. doi: 10.14744/agri.2021.26032. PMID 34671954
18: Barker FG, Jannetta PJ, Bissonette DJ, Larkins MV, Jho HD. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334(17):1077-83. PMID 8598865
19: Baskaran RK, Krishnamoorthy MS. Numb chin syndrome--a reflection of systemic malignancy. World J Surg Oncol 2006;4:52. PMID 16899116
20: Baydoun J, Lin A, Miya J. Low-dose fosphenytoin for aborting acute trigeminal neuralgia pain: a case report. Clin Pract Cases Emerg Med 2023;7(3):182-4. PMID 37595315
21: Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 2019;26(6):831-49.** PMID 30860637
22: Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol 2020;19(9):784-96. PMID 32822636
23: Benoliel R, Gaul C. Persistent idiopathic facial pain. Cephalalgia 2017;37(7):680-91. PMID 28425324
24: Bergouignan M. Cures heureuses de névralgies faciales essentielles par le diphenylhydantoinate de soude. Rev Laryngol Otol Rhinol (Bord) 1942;63:34-41.
25: Berti A, Ibars G, Wu X, et al. Evaluation of CyberKnife radiosurgery for recurrent trigeminal neuralgia. Cureus 2018;10(5):e2598. PMID 30013862
26: Besi E, Boniface DR, Cregg R, Zakrzewska JM. Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). J Headache Pain 2015;16:563. PMID 26335440
27: Bethamcharla R, Yugrakh MS, Chang YF, Sekula RF Jr. Long-term effectiveness of early versus late microvascular decompression for trigeminal neuralgia secondary to arterial compression. Eur J Neurol 2025;32(6):e70184. PMID 40470542
28: Bicimveren MS, Karadaş Ö, Cüce F. Correlations between the blink reflex and magnetic resonance imaging in patients with trigeminal neuralgia. Acta Neurol Belg 2025;125(2):481-7. PMID 39841405
29: Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29(6):393-408. PMID 19432499
30: Blom S. Tic douloureux treated with new anticonvulsant; experiences with G 32883. Arch Neurol 1963;9:285-90. PMID 14049402
31: Bora N, Parihar P, Raj N, Shetty N, Nunna B. A systematic review of the role of magnetic resonance imaging in the diagnosis and detection of neurovascular conflict in patients with trigeminal neuralgia. Cureus 2023;15(9):e44614. PMID 37799230
32: Braga FM, Bonatelli Ade P, Suriano I, Canteras M. Familial trigeminal neuralgia. Surg Neurol 1986;26(4):405-8. PMID 3750201
33: Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes in patients exposed to onabotulinumtoxinA treatment: a cumulative 29-year safety update. Neurology 2023;101(2):e103-13. PMID 37137724
34: Brown JA, Coursaget C, Preul MC, Sangvai D. Mercury water and cauterizing stones: Nicolas André and tic douloureux. J Neurosurg 1999;90(5):977-81. PMID 10223470
35: Caramia F, Di Renzo A, Fiorelli M, et al. Structural alterations in occipital cortices in trigeminal neuralgia: a voxel- and surface-based morphometric MRI study. J Headache Pain 2025;26(1):162. PMID 40670915
36: Chakraborty AR, Sunshine K, Miller JP, Sweet JA. Current applications of ablative therapies for trigeminal neuralgia. Neurosurg Clin N Am 2023;34(2):285-90. PMID 36906334
37: Chaudhry P, Friedman DI. Intravenous lidocaine treatment in classical trigeminal neuralgia with concomitant persistent facial pain. Headache 2014;54(8):1376-9. PMID 24845616
38: Chen HI, Lee JY. The measurement of pain in patients with trigeminal neuralgia. Clin Neurosurg 2010;57:129-33. PMID 21280505
39: Chen Q, Yi DI, Perez JN, et al. The molecular basis and pathophysiology of trigeminal neuralgia. Int J Mol Sci 2022;23(7):3604. PMID 35408959
40: Cheng JS, Lim DA, Chang EF, Barbaro NM. A review of percutaneous treatments for trigeminal neuralgia. Neurosurgery 2014;10 Suppl 1:25-33. PMID 24509496
41: Cheshire WP. Cranial neuralgias. Continuum (Minneap Minn) 2015;21(4 Headache):1072-85.** PMID 26252592
42: Cheshire WP. Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis. J Pain Symptom Manage 2001;21(6):506-10. PMID 11397609
43: Cole CD, Liu JK, Apfelbaum RI. Historical perspectives on the diagnosis and treatment of trigeminal neuralgia. Neurosurg Focus 2005;18(5):E4. PMID 15913280
44: Cruccu G. Trigeminal neuralgia. Continuum (Minneap Minn) 2017;23(2, Selected Topics in Outpatient Neurology):396-420.** PMID 28375911
45: Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology 2016;87(2):220-8.** PMID 27306631
46: Cruccu G, Stefano GD, Truini A. Trigeminal neuralgia. N Engl J Med 2020;383(8):754-62. PMID 32813951
47: Dandy WE. An Operation for the Cure of Tic Doloureux: Partial Secton of the Sensory Root at the Pons. Arch Surg 1929;18:687-734.
48: Dandy WE. Concerning the cause of trigeminal neuralgia. Am J Surg 1934;24:447-55.
49: Danyluk HJ, Dhillon A, Ayri A, Beaulieu C, Sankar T. Nerve matters: longitudinal microstructural change in the trigeminal nerve is associated with durable pain relief after surgery for trigeminal neuralgia. Cephalalgia 2025;45(9):3331024251369827. PMID 40891642
50: De Stefano G, Mollica C, Leone C, et al. Trigeminal reflex testing abnormalities as a predictive model for distinguishing classical and idiopathic trigeminal neuralgia. Clin Neurophysiol 2025;171:61-6. PMID 39889483
51: De Toledo IP, Conti Réus J, Fernandes M, et al. Prevalence of trigeminal neuralgia: a systematic review. J Am Dent Assoc 2016;147(7):570-6.e2. PMID 27017183
52: Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain 2002;18(1):4-13. PMID 11803297
53: Dewhurst K. A symposium on trigeminal neuralgia; with contributions by Locke, Sydenham, and other eminent seventeenth century physicians. J Hist Med Allied Sci 1957;12(1):21-36. PMID 13406256
54: Di Carlo DT, Benedetto N, Perrini P. Clinical outcome after microvascular decompression for trigeminal neuralgia: a systematic review and meta-analysis. Neurosurg Rev 2022;46(1):8. PMID 36481917
55: Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain 2014;15(1):34. PMID 24912658
56: Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain 2019;20(1):20. PMID 30782116
57: Di Stefano G, Yuan JH, Cruccu G, Waxman SG, Dib-Hajj SD, Truini A. Familial trigeminal neuralgia - a systematic clinical study with a genomic screen of the neuronal electrogenisome. Cephalalgia 2020;40(8):767-77. PMID 31928344
58: Diaz I, Bamberger DM. Acute sinusitis. Semin Respir Infect 1995;10(1):14-20. PMID 7761709
59: Divya KS, Moran NA, Atkin PA. Numb chin syndrome: a case series and discussion. Br Dent J 2010;208(4):157-60. PMID 20186196
60: Dixon DD, Sze K, Elfman JH, Gue S. Keeping it simple: a case report on atomized intranasal 1% lidocaine as an effective treatment for pain crisis due to trigeminal neuralgia. Cureus 2025;17(11):e97652. PMID 41450385
61: Dong B, Xu R, Lim M. The pathophysiology of trigeminal neuralgia: a molecular review. J Neurosurg 2023;139(5):1471-9. PMID 37922556
62: Dong G, Li Q, Sun J, et al. Long-term outcomes of Gamma Knife radiosurgery for trigeminal neuralgia patients with or without concomitant continuous pain. Medicine (Baltimore) 2024;103(51):e41026. PMID 39705465
63: Duff JM, Spinner RJ, Lindor NM, Dodick DW, Atkinson JL. Familial trigeminal neuralgia and contralateral hemifacial spasm. Neurology 1999;53(1):216-8. PMID 10408564
64: Evans RW. Peripheral nerve blocks and trigger point injections in headache management: trigeminal neuralgia does not respond to occipital nerve block. Headache 2010;50(7):1215-6. PMID 20649653
65: Evans RW, Kirby S, Purdy RA. Numb chin syndrome. Headache 2008;48(10):1520-4. PMID 19076650
66: Faber CG, Attal N, Lauria G, et al. Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study. EClinicalMedicine 2023;59:101971. PMID 37152360
67: Fan Y, Luka R, Noronha A. Non-Hodgkin lymphoma presenting with numb chin syndrome. BMJ Case Rep 2011;2011:bcr0120113712. PMID 22696665
68: Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9(10):1543-6. PMID 18855540
69: Finucane S, Dalwadi P, Mudaliar K, Hurtuk A. Trigeminal trophic syndrome: a systematic review. Am J Otolaryngol 2024;45(4):104354. PMID 38759434
70: Fishbein NS, Bakhshaie J, Greenberg J. Suicidal ideation and self-injury in trigeminal neuralgia. J Pain Res 2025;18:2003-10. PMID 40241816
71: Fooanant S, Angkurawaranon S, Angkurawaranon C, Roongrotwattanasiri K, Chaiyasate S. Sphenoid sinus diseases: a review of 1,442 patients. Int J Otolaryngol 2017;2017:9650910. PMID 29090009
72: Fromm GH, Graff-Radford SB, Terrence CF, Sweet WH. Pre-trigeminal neuralgia. Neurology 1990;40(10):1493-5. PMID 2215936
73: Fromm GH, Terrence CF, Maroon JC. Trigeminal neuralgia. Current concepts regarding etiology and pathogenesis. Arch Neurol 1984;41(11):1204-7. PMID 6487105
74: Gambeta E, Chichorro JG, Zamponi GW. Trigeminal neuralgia: an overview from pathophysiology to pharmacological treatments. Mol Pain 2020;16:1744806920901890. PMID 31908187
75: Gardner WJ, Miklos MV. Response of trigeminal neuralgia to decompression of sensory root; discussion of cause of trigeminal neuralgia. J Am Med Assoc 1959;170(15):1773-6. PMID 13672767
76: Gauer RL, Semidey MJ. Diagnosis and treatment of temporomandibular disorders. Am Fam Physician 2015;91(6):378-86. PMID 25822556
77: Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347(5):340-6. PMID 12151472
78: Goadsby PJ. Raeder's syndrome [corrected]: paratrigeminal paralysis of the oculopupillary sympathetic system. J Neurol Neurosurg Psychiatry 2002;72(3):297-9. PMID 11861683
79: Grant GJ, Schechter D, Redai I, Lax J. Transnasal topical sphenopalatine ganglion block to treat tension headache in a pregnant patient. Int J Obstet Anesth 2014;23(3):292-3. PMID 24986563
80: Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008;71(15):1183-90. PMID 18716236
81: Hajikarimloo B, Tos SM, Mohammadzadeh I, et al. Efficacy and safety of microvascular decompression in trigeminal neuralgia secondary to multiple sclerosis: a systematic review and meta-analysis. Acta Neurol Belg 2025a. [Epub ahead of print] PMID 41082162
82: Hajikarimloo B, Tos SM, Mohammadzadeh I, et al. Radiofrequency rhizotomy for multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis. BMC Surg 2025b;25(1):413. PMID 40999388
83: Han KR, Kim C, Chae YJ, Kim DW. Efficacy and safety of high concentration lidocaine for trigeminal nerve block in patients with trigeminal neuralgia. Int J Clin Pract 2008;62(2):248-54. PMID 18036166
84: Hassan AF, Sheakh AA, Badran SA, Mahmood AA, Alhamdani FY. Misdiagnosis-driven dental extractions in patients with trigeminal neuralgia: a retrospective study. J Multidiscip Healthc 2025;18:1999-2005. PMID 40230490
85: Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 3rd edition. Cephalalgia 2018;38(1):1-211.** PMID 29368949
86: Herta J, Schmied T, Loidl TB, et al. Microvascular decompression in trigeminal neuralgia: predictors of pain relief, complication avoidance, and lessons learned. Acta Neurochir (Wien) 2021;163(12):3321-3336. PMID 34674027
87: Herzberg L. Familial trigeminal neuralgia. Arch Neurol 1980;37(5):285-6. PMID 7387447
88: Horn AC, Kolahi Sohrabi A, Chan MD, et al. Gamma Knife radiosurgery for relapsing trigeminal neuralgia following microvascular decompression. J Neurosurg 2024:1-9. PMID 39612504
89: Houshi S, Tavallaei MJ, Barzegar M, et al. Prevalence of trigeminal neuralgia in multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 2022;57:103472. PMID 34986455
90: Hughes MA, Frederickson AM, Branstetter BF, Zhu X, Sekula RF Jr. MRI of the trigeminal nerve in patients with trigeminal neuralgia secondary to vascular compression. AJR Am J Roentgenol 2016;206(3):595-600. PMID 26901017
91: Jacques N, Karoutsos S, Marais L, Nathan-Denizot N. Quality of life after trigeminal nerve block in refractory trigeminal neuralgia: a retrospective cohort study and literature review. J Int Med Res 2022;50(10):3000605221132027. PMID 36281027
92: Jannetta PJ. Treatment of trigeminal neuralgia by suboccipital and transtentorial cranial operations. Clin Neurosurg 1977;24:538-49. PMID 583698
93: Jiao L, Ye H, Lv J, et al. A systematic review of repeat microvascular decompression for recurrent or persistent trigeminal neuralgia. World Neurosurg 2022;158:226-33. PMID 34875391
94: Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth 2006;97:559-63. PMID 16882684
95: Katsuki M, Kawamura S, Kashiwagi K, Tachikawa S, Koh A. Erenumab in the treatment of comorbid trigeminal neuralgia in patients with migraine. Cureus 2023;15(3):e35913. PMID 37038564
96: Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol 1990;27(1):89-95. PMID 2301931
97: Khaboushan AS, Maroufi SF, Jarrah N, Moafi M, et al. Comparison of stereotactic radiosurgery and rhizotomy for trigeminal neuralgia: a systematic review and meta-analysis. Neurosurg Rev 2025;48(1):613. PMID 40833460
98: Khan AU, Khachemoune A. Trigeminal trophic syndrome: an updated review. Int J Dermatol 2019;58(5):530-7. PMID 29931799
99: Kim H, Oh SY. The clinical features and outcomes of Tolosa-Hunt syndrome. BMC Ophthalmol 2021;21(1):237. PMID 34044807
100: Klasser GD, Gremillion HA, Epstein JB. Dental treatment for patients with neuropathic orofacial pain. J Am Dent Assoc 2013;144(9):1006-8. PMID 23989838
101: Kobayashi K, Fukuoka T, Obata K, et al. Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with adelta/c-fibers and colocalization with trk receptors. J Comp Neurol 2005;493(4):596-606. PMID 16304633
102: Kramer DE, Barrett C, Sandoval-Consuegra J, et al. Comparison of endoscope, exoscope, and microscope visualization during microvascular decompression for trigeminal neuralgia: a single-center experience of 135 surgeries. Neurosurg Focus 2025;59(3):E17. PMID 40889383
103: Kumar A, Anwar SSM, Bilal K, Ahmed A, Samnani S, Zafar B. Frequency of trigeminal neurovascular contacts identified on 3D-fast imaging employing steady-state acquisition magnetic resonance imaging in asymptomatic adults. Surg Neurol Int 2025a;16:31. PMID 39926468
104: Kumar A, Kubota Y, Yokosako S, Chernov M. Radiological characteristics of the affected trigeminal nerve in cases of trigeminal neuralgia caused by pure venous conflict. World Neurosurg 2025b;194:123500. PMID 39581467
105: Kurzbuch AR, Ellenbogen JR, Keric N, Tronnier V, Tuleasca C. Outcomes of trigeminal nerve microsurgical internal neurolysis for trigeminal neuralgia without neurovascular conflict: a systematic review and meta-analysis. Neurosurg Rev 2025;48(1):678. PMID 41051437
106: Laccourreye O, Werner A, Garcia D, Malinvaud D, Tran Ba Huy P, Bonfils P. First bitemsyndrome. Eur Ann Otorhinolaryngol Head Neck Dis 2013;130(5):269-73. PMID 23890788
107: Laurencet FM, Anchisi S, Tullen E, Dietrich PY. Mental neuropathy: report of five cases and review of the literature. Crit Rev Oncol Hematol 2000;34(1):71-9. PMID 10781749
108: Lin KH, Chen YT, Fuh JL, Wang SJ. Increased risk of trigeminal neuralgia in patients with migraine: a nationwide population-based study. Cephalalgia 2016;36(13):1218-227. PMID 26692399
109: Lin PJ, Li CS, Chang GS. Experiences in the management of cerebellopontine angle tumour: an analysis of 64 cases. Gaoxiong Yi Xue Ke Xue Za Zhi 1991;7(6):329-33. PMID 1856892
110: Liu M, Zhong J, Xia L, Dou N, Li S. The expression of voltage-gated sodium channels in trigeminal nerve following chronic constriction injury in rats. Int J Neurosci 2019;129(10):955-62. PMID 30889362
111: Lv G, Zhang Z, Hao Q, et al. Neurofunctional divergence between classical and idiopathic trigeminal neuralgia: a large-cohort resting-state fMRI study of 139 patients. Clin Neurol Neurosurg 2025;258:109127. PMID 40886511
112: Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Concomitant persistent pain in classical trigeminal neuralgia--evidence for different subtypes. Headache 2014a;54(7):1173-83. PMID 24842632
113: Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia--a prospective systematic study of clinical characteristics in 158 patients. Headache 2014b;54(10):1574-82. PMID 25231219
114: MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123(Pt 4):665-76. PMID 10733998
115: Madley-Dowd P, Ahlqvist VH, Forbes H, et al. Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes. Nat Commun 2024;15(1):9640. PMID 39548057
116: Manahan AP, Malesker MA, Malone PM. Sphenopalatine ganglion block relieves symptoms of trigeminal neuralgia: a case report. Nebr Med J 1996;81(9):306-9. PMID 8885638
117: Mazzapicchi E, Broggi M, Restelli F, et al. Trigeminal neuralgia in multiple sclerosis: proposal of surgical flowchart and long-term outcome evaluation in a mono-istitutional cohort. Neurol Sci 2025;46(4):1789-98. PMID 39638949
118: McKinney S, Whittington KD, Collins SK. Care strategies for patients with trigeminal neuralgia. Decisions Dentistry 2021;7(6):32-5.
119: Mignogna MD, Pollio A, Fortuna G, Leuci S, Ruoppo E, Adamo D, Zarrelli C. Unexplained somatic comorbidities in patients with burning mouth syndrome: a controlled clinical study. J Orofac Pain 2011;25(2):131-40. PMID 21528120
120: Mohamed MW, Irem-Oko F, Sheikh A, Phillips N, Mckinlay J, Anderson I. Lidocaine infusion for the treatment of intractable trigeminal neuralgia: retrospective case series and systematic review. Acta Neurochir (Wien) 2025;167(1):259. PMID 41021111
121: Moisset X, Villain N, Ducreux D, et al. Functional brain imaging of trigeminal neuralgia. Eur J Pain 2011;15(2):124-31. PMID 20609605
122: Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. Br J Anaesth 2019;123(2):e385-96. PMID 31208761
123: Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia 2011;31(15):1542-8. PMID 21960648
124: Mullins CF, Fuccaro M, Pang D, Min L, Andreou AP, Lambru G. A single infusion of intravenous lidocaine for primary headaches and trigeminal neuralgia: a retrospective analysis. Front Neurol 2023;14:1202426. PMID 37638187
125: Munoz-Vendrell A, Teixidor S, Sala-Padró J, Campoy S, Huerta-Villanueva M. Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: a retrospective analysis of 144 cases. Cephalalgia 2022;42(10):1031-8. PMID 35469475
126: Munoz-Vendrell A, Tena-Cucala R, Campoy S, et al. Oral lacosamide for the treatment of refractory trigeminal neuralgia: a retrospective analysis of 86 cases. Headache 2023;63(4):559-64. PMID 37036126
127: Munoz-Vendrell A, Valín-Villanueva P, Tena-Cucala R, Campoy S, Martínez-Yélamos S, Huerta-Villanueva M. Second-line pharmacological treatment strategies for trigeminal neuralgia: a retrospective comparison of lacosamide, gabapentin and baclofen. Headache 2025;65(7):1116-23. PMID 40341553
128: Naderi Y, Rad M, Sadatmoosavi A, et al. Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: a systematic review. Clin Exp Dent Res 2024;10(2):e882. PMID 38558383
129: Nagib M, Hood P, Matteo J. Sphenopalatine ganglion block: treatment of migraine and trigeminal neuralgia associated with multiple sclerosis. Cureus 2020;12(6):e8522. PMID 32656035
130: Noro S, Endo H, Asayama B, et al. Intravenous fosphenytoin therapy for the rescue of acute trigeminal neuralgia crisis in pre- and post-neurosurgical patients: a retrospective observational study. Front Neurol 2025;15:1493274. PMID 39839861
131: Noro S, Seo Y, Honjo K, Okuma M, et al. Intravenous fosphenytoin therapy for rescue of acute trigeminal neuralgia crisis in patients awaiting neurosurgical procedures: a cross-sectional study. J Clin Neurosci 2021;94:59-64. PMID 34863463
132: Nurmikko TJ, Eldridge PR. Trigeminal neuralgia--pathophysiology, diagnosis and current treatment. Br J Anaesth 2001;87(1):117-32. PMID 11460800
133: Obermann M, Yoon MS, Ese D, et al. Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology 2007;69(9):835-41. PMID 17724285
134: Ogle OE. Salivary gland diseases. Dent Clin North Am 2020;64(1):87-104. PMID 31735235
135: Orfanou C, Gkaniou A, Rekatsina M, et al. Sphenopalatine ganglion block using the Tx360 nasal applicator for trigeminal neuralgia: a prospective observational pilot study. Cureus 2025;17(2):e78727. PMID 40065877
136: Oyewole SO, Owosho AA. Orofacial adverse events associated with immune checkpoint inhibitors: using a large real-world dataset. Oral Surg Oral Med Oral Pathol Oral Radiol 2026;141(2):170-5. PMID 41107115
137: Pack AM, Oskoui M, Williams Roberson S, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: practice guideline from the AAN, AES, and SMFM. Neurology 2024;102(11):e209279. PMID 38748979
138: Parascandolo E, Levinson K, Rizzoli P, Sharon R. Efficacy of erenumab in the treatment of trigeminal neuralgia: a retrospective case series. Neurol Clin Pract 2021;11(3):227-31. PMID 34484889
139: Pareja JA, Barón M, Gili P, et al. Objective assessment of autonomic signs during triggered first division trigeminal neuralgia. Cephalalgia 2002;22(4):251-5. PMID 12100085
140: Park HJ, Ahn JM, Ryu JW. Post-traumatic trigeminal neuropathic pain: a narrative review of understanding, management, and prognosis. Biomedicines 2024;12(9):2058. PMID 39335571
141: Parker M, Xia Y, Alfonzo Horowitz M, et al. Impact of preoperative medical management on postoperative outcomes after index percutaneous rhizotomy for trigeminal neuralgia. Neurosurg Focus 2025;59(3):E8. PMID 40889406
142: Patra DP, Savardekar AR, Dossani RH, Narayan V, Mohammed N, Nanda A. Repeat Gamma Knife radiosurgery versus microvascular decompression following failure of GKRS in trigeminal neuralgia: a systematic review and meta-analysis. J Neurosurg 2018:1-10. PMID 30485193
143: Pearce JM. Trigeminal neuralgia (Fothergill's disease) in the 17th and 18th centuries. J Neurol Neurosurg Psychiatry 2003;74(12):1688. PMID 14638891
144: Perloff MD, Chung JS. Urgent care peripheral nerve blocks for refractory trigeminal neuralgia. Am J Emerg Med 2018;36(11):2058-60. PMID 30119988
145: Pinto MJ, Gomes A, Pinto M, Abreu P, Costa A. Treatment of acute exacerbations of trigeminal neuralgia in the emergency department: a retrospective case series. Headache 2022;62(8):1002-6. PMID 36005285
146: Poullet Z, Redon S, Gravier-Dumonceau R, Donnet A. "Status trigeminal neuralgia": analysis of 39 cases and proposal for diagnostic criteria. Rev Neurol (Paris) 2024;180(7):689-97. PMID 38789382
147: Pour-Rashidi A, Shirani M, Zali Z, Amirjamshidi A. Trigeminal neuralgia or hemifacial spasm due to vertebrobasilar dolichoectasia: a single-center case series and systematic review. Neurosurg Focus 2025;59(3):E6. PMID 40889404
148: Rimmele F, Maschke H, Großmann A, Jürgens TP. A case report: numb chin syndrome due to thalamic infarction: a rare case. BMC Neurol 2019;19(1):303. PMID 31783736
149: Robblee J. A pain in the ear: two case reports of nervus intermedius neuralgia and narrative review. Headache 2021;61(3):414-21. PMID 33586784
150: Romanelli P, Conti A, Redaelli I, et al. Cyberknife radiosurgery for trigeminal neuralgia. Cureus 2019;11(10):e6014. PMID 31815078
151: Rose FC. Trigeminal neuralgia. Arch Neurol 1999;56(9):1163-4. PMID 10488822
152: Sade B, Lee JH. Microvascular decompression for trigeminal neuralgia. Neurosurg Clin N Am 2014;25(4):743-9. PMID 25240661
153: Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache 2014 Winter;28(1):6-27. PMID 24482784
154: Schnell S, Marrodan M, Acosta JN, Bonamico L, Goicochea MT. Trigeminal neuralgia crisis - intravenous phenytoin as acute rescue treatment. Headache 2020;60(10):2247-53. PMID 32981076
155: Seha B, Bogosavljevic V, Grujicic D, et al. Outcomes, predictors of retreatment, and complications after repeat gamma knife radiosurgery for trigeminal neuralgia: a single-center retrospective cohort study. Cureus 2025;17(8):e89485. PMID 40772001
156: Shah RJ, Padalia D. Glossopharyngeal Neuralgia 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. PMID 31082085
157: Sharav Y, Haviv Y, Benoliel R. Orofacial migraine or neurovascular orofacial pain from pathogenesis to treatment. Int J Mol Sci 2023;24(3):2456. PMID 36768779
158: Sheehan J, Pan HC, Stroila M, Steiner L. Gamma knife surgery for trigeminal neuralgia: outcomes and prognostic factors. J Neurosurg 2005;102(3):434-41. PMID 15796376
159: Sindou M, Brinzeu A. Topography of the pain in classical trigeminal neuralgia: insights into somatotopic organization. Brain 2020;143(2):531-40. PMID 31930326
160: Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002;18(1):22-7. PMID 11803299
161: Singh PM, Kaur M, Trikha A. An uncommonly common: glossopharyngeal neuralgia. Ann Indian Acad Neurol 2013;16(1):1-8. PMID 23661955
162: Siqueira SR, Alves B, Malpartida HM, Teixeira MJ, Siqueira JT. Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. Neuroscience 2009;164(2):573-7. PMID 19699781
163: Sjaastad O, Bakketeig LS. The rare, unilateral headaches. Vågå study of headache epidemiology. J Headache Pain 2007;8(1):19-27. PMID 17221345
164: Smith RM, Hassan A, Robertson CE. Numb chin syndrome. Curr Pain Headache Rep 2015;19(9):44. PMID 26210355
165: Smyth P, Greenough G, Stommel E. Familial trigeminal neuralgia: case reports and review of the literature. Headache 2003;43(8):910-5. PMID 12940815
166: Stavropoulou E, Argyra E, Zis P, Vadalouca A, Siafaka I. The effect of intravenous lidocaine on trigeminal neuralgia: a randomized double blind placebo controlled trial. ISRN Pain 2014;2014:853826. PMID 27335883
167: Steel SJ, Robertson CE. First bite syndrome: what neurologists need to know. Curr Pain Headache Rep 2021;25(5):31. PMID 33761012
168: Svedung Wettervik T, Snel D, Kristiansson P, Ericson H, Abu Hamdeh S. Incidence of trigeminal neuralgia: a population-based study in Central Sweden. Eur J Pain 2023;27(5):580-7. PMID 36680398
169: Swain BP, Vidhya S, Jadon A, Chandra KN, Kumar S. Trigeminal neuralgia in pregnancy: a management challenge. Pain Pract 2018;18(3):368-73. PMID 28574640
170: Sweet WH, Wepsic JG. Controlled thermocoagulation of trigeminal ganglion and rootlets for differential destruction of pain fibers. 1. Trigeminal neuralgia. J Neurosurg 1974;40(2):143-56. PMID 4587949
171: Tai AX, Nayar VV. Update on trigeminal neuralgia. Curr Treat Options Neurol 2019;21(9):42. PMID 31367794
172: Tan M, Kim E, Koren G, Bozzo P. Botulinum toxin type A in pregnancy. Can Fam Physician 2013;59(11):1183-4. PMID 24235190
173: Tang M, Devarajan A, Huo L, et al. Identifying associated comorbidities in the development of trigeminal neuralgia: a propensity-matched analysis of the National Inpatient Sample. Clin Neurol Neurosurg 2025;255:108985. PMID 40451122
174: Thomas DC, Kodaganallur Pitchumani P, Barmak AB, Talluri S, Jiang W. Autonomic features of craniofacial neuralgias: a systematic review with meta-analysis. J Oral Facial Pain Headache 2024;38(3):15-31. PMID 39800568
175: Thomas KL, Vilensky JA. The anatomy of vascular compression in trigeminal neuralgia. Clin Anat 2014;27(1):89-93. PMID 23381734
176: Trousseau A. De la névralgie épileptiforme. Arch Gen Med 1853;1:33-44.
177: Tugend M, Joncas CT, Chang YF, Jaoui Y, Sekula RF Jr. Update and evaluation of a preoperative scoring system to predict long-term outcomes after microvascular decompression in trigeminal neuralgia. Oper Neurosurg 2025a;29(6):824-31. PMID 40391987
178: Tugend M, Joncas CT, Traylor K, Hughes MA, Sekula RF. An analysis of diffusion tensor imaging in classical trigeminal neuralgia. Cephalalgia 2025b;45(7):3331024251322505. PMID 40739886
179: Tuleasca C, Régis J, Sahgal A, et al. Stereotactic radiosurgery for trigeminal neuralgia: a systematic review. J Neurosurg 2018;130(3):733-57. PMID 29701555
180: U.S. Food and Drug Administration. Public meeting on neuropathic pain associated with peripheral neuropathy patient-focused drug development. Available at: www.fda.gov. Accessed October 2023.
181: Valeri F, Della Pepa GM, Grilli FV, et al. Repeated radiosurgery for recurrent or refractory trigeminal neuralgia: a systematic review and meta-analysis. Neurosurg Rev 2025;48(1):720. PMID 41108438
182: Vasappa CK, Kapur S, Krovvidi H. Trigeminal neuralgia. BJA Education 2016;16(10):353-6.
183: von Eckardstein KL, Keil M, Rohde V. Unnecessary dental procedures as a consequence of trigeminal neuralgia. Neurosurg Rev 2015;38(2):355-60. PMID 25418511
184: Wang S, Chen G, Xie J, et al. Development and validation of a predictive model for poor initial outcomes after Gamma Knife radiosurgery for trigeminal neuralgia: a prognostic correlative analysis. J Neurosurg 2025;143(4):987-98. PMID 40446349
185: Wilson KF, Meier JD, Ward PD. Salivary gland disorders. Am Fam Physician 2014;89(11):882-8. PMID 25077394
186: Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22(2):341-7. PMID 8838194
187: Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011;152(3 Suppl):S2-15. PMID 20961685
188: Worm J, Heinskou TB, Rochat P, et al. Five-year prospective outcomes of medical management and microvascular decompression in trigeminal neuralgia. J Neurol 2025;272(10):701. PMID 41102594
189: Wyllie JW, Kern EB, Djalilian M. Isolated sphenoid sinus lesions. Laryngoscope 1973;83(8):1252-65. PMID 4758128
190: Xu R, Xie ME, Jackson CM. Trigeminal neuralgia: current approaches and emerging interventions. J Pain Res 2021;14:3437-63. PMID 34764686
191: Xu W, Zhang J, Wang Y, Wang L, Wang X. Changes in the expression of voltage-gated sodium channels Nav1.3, Nav1.7, Nav1.8, and Nav1.9 in rat trigeminal ganglia following chronic constriction injury. Neuroreport 2016;27(12):929-34. PMID 27327156
192: Yang S, Chang MC. Effect of repetitive transcranial magnetic stimulation on pain management: a systematic narrative review. Front Neurol 2020;11:114. PMID 32132973
193: Yeung AW, Wong NS. The historical roots of visual analog scale in psychology as revealed by reference publication year spectroscopy. Front Hum Neurosci 2019;13:86. PMID 30914939
194: Yu B, Zhang W, Zhao C, Xing Y, Meng L, Luo F. Effectiveness, safety, and predictors of response to 5% lidocaine-medicated plaster for the treatment of patients with trigeminal neuralgia: a retrospective study. Ann Pharmacother 2023;57(5):527-34. PMID 36039508
195: Zakrzewska JM, Palmer J, Morisset V, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol 2017;16(4):291-300. PMID 28216232
196: Zhang C, Hu H, Das SK, et al. Structural and functional brain abnormalities in trigeminal neuralgia: a systematic review. J Oral Facial Pain Headache 2020;34(3):222-35. PMID 32870951
197: Zhao C, Shrestha N, Ren H, et al. The PATCH trial: 5% lidocaine-medicated plaster for trigeminal neuralgia-Results of a multicentric, enriched enrollment, randomized withdrawal, double-blind, vehicle-controlled, parallel-group study. Headache 2024a;64(10):1318-28. PMID 39193836
198: Zhao W, Yin C, Ma L, Ding M, Kong W, Wang Y. Predictive value of MRI for identifying symptomatic neurovascular compressions in classical trigeminal neuralgia: a PRISMA-compliant meta-analysis. BMC Neurol 2024b;24(1):466. PMID 39614218
199: Ziegeler C, Beikler T, Gosau M, May A. Idiopathic facial pain syndromes–an overview and clinical implications. Dtsch Arztebl Int 2021;118(6):81-7. PMID 33827748
200: References especially recommended by the author or editor for general reading.

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Jennifer Robblee MD MSc FRCPC

Dr. Robblee of Barrow Neurological Institute received research support from Barrow Neurological Foundation as principal investigator and served on advisory boards for Tonix.
See Profile

Editor

Hsiangkuo Yuan MD PhD FAHS

Dr. Yuan of Jefferson Health-Thomas Jefferson University Hospitals received a consultant honorarium from Abbvie, Cerenovous, Pfizer, and Salvia.
See Profile

Former Authors

Derek Notch MD
Yi Pan MD PhD
Olivia Kingsford DO
Stephen D Silberstein MD

Patient Profile

Age range of presentation: Classical: typically 40+ yearsof age

Secondary to multiple sclerosis: younger than classical
Sex preponderance: female>male, up to 2:1 or 3:1
Heredity: familial in 1% to 2%

autosomal dominant inheritance may be a factor
Population groups selectively affected: No population group selectively affected
Occupation groups selectively affected: None selectively affected

ICD & OMIM codes

ICD-10: Atypical trigeminal neuralgia: G50.1

Painful trigeminal neuralgia attributed to herpes zoster: B02.29

Post herpetic trigeminal neuralgia: B02.22

Postherpetic geniculate ganglionitis: B02.21

Posttraumatic trigeminal neuropathy: G50.8

Tic douloureux: G50.0

Trigeminal nerve disorder: G50.8

Trigeminal neuralgia: G50.0

Trigeminal neuropathic pain: G50.9

Trigeminal neuropathy: G50.8
ICD-11: Trigeminal neuralgia: 8B82.0

Postherpetic polyneuropathy: 1E91.5
OMIM: Trigeminal neuralgia: 190400

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Trigeminal neuralgia

Associated Disorders

Arteriovenous malformation involving cranial nerves
Arteriovenous dural fistula
Cerebellopontine angle abscess
Cerebellopontine angle mass lesions
Cerebellopontine angle tumors (Schwannoma, meningioma)
- Herpes zoster
- MS plaque
- Multiple sclerosis
- Nasopharyngeal carcinoma
- Neurovascular compression
- Neurovascular loop
- Petrous bone osteoma
- Posterior fossa abscess
- Posterior fossa AVM
- Posterior fossa mass lesions
- Posterior fossa tumors
- Temporomandibular joint dysfunction
- TMJ dysfunction
- Vascular compression
- Vascular loop
- Vascular malformation

Differential Diagnosis

Dental pain
Acute maxillary rhinosinusitis
Sphenoid sinus disease
Temporomandibular disorders
Salivary duct blockage
- Trigeminal autonomic cephalgias (sunct, suna)
- Migraine
- Glossopharyngeal neuralgia
- Nervus intermedius neuralgia
- Persistent idiopathic facial pain
- Tolosa Hunt syndrome
- Paratrigeminal oculosympathetic syndrome
- Burning mouth syndrome

Also Relevant

Cluster headache
Herpes zoster oticus
Indomethacin-responsive headache syndromes
Migraine: clinical aspects
Multiple sclerosis: presentation and course
- Neuropathic pain: treatment
- Pain
- Pain, headache, and oromandibular structures
- Sporadic schwannomas and neurofibromas
- SUNCT syndrome
- Tension-type headache
- Varicella-zoster virus infections of the nervous system

Clinical Categories

Headache & Pain

Trigeminal neuralgia

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Overview of clinical presentation

ICHD-3 Diagnostic criteria for trigeminal neuralgia

Classical trigeminal neuralgia

Secondary trigeminal neuralgia

Idiopathic trigeminal neuralgia

Painful trigeminal neuropathy

Painful trigeminal neuropathy attributed to herpes zoster

Post-herpetic trigeminal neuropathy

Painful post-traumatic trigeminal neuropathy

Painful trigeminal neuropathy attributed to another disorder

Idiopathic painful trigeminal neuropathy

Prognosis

Complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Neurovascular conflict from classical trigeminal neuralgia

Secondary trigeminal neuralgia in the setting of multiple sclerosis

Proposed theory for idiopathic trigeminal neuralgia

Pathophysiology of trigeminal neuropathy

Epidemiology

Classical trigeminal neuralgia

Secondary trigeminal neuralgia

Idiopathic trigeminal neuralgia

Painful trigeminal neuropathies

Differential diagnosis

Confusing conditions: Orofacial and dental sources

Acute maxillary rhinosinusitis

Sphenoid sinus disease

Salivary duct blockage

Trigeminal autonomic cephalgias

Migraine

Glossopharyngeal neuralgia

Nervus intermedius neuralgia

Tolosa Hunt syndrome

Paratrigeminal oculosympathetic syndrome

Table 1. A Comparison of Trigeminal Neuralgia and Other Similarly Presenting Conditions

Associated or underlying disorders

Diagnostic workup

Step 1: History

Step 2: Physical exam

Step 3: Investigations

Management

Sodium channel blockers

Second-line treatments

New potential pharmacologic options

Acute pharmacologic management

Surgical management

Microvascular decompression

Stereotactic radiosurgery

Percutaneous techniques

Multidisciplinary care

Outcomes

Special considerations

Pregnancy

Procedures

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Suzetrigine

Atogepant

Headache associated with HIV and AIDS

Primary exercise headache

Chiropractic manipulation: neurologic complications

This is an article preview.
Start a Free Account
to access the full version.